short_id,citation,publication_year,study_design,population_description,low_arousal_proxy_definition,n_total,setting,intervention_category,intervention_protocol,comparator,exposure_duration_days,outcome_domain,outcome_measure,outcome_timepoint,effect_direction,effect_size_reported,habituation_or_tolerance_signal,adherence_or_compliance,notes,anchors,pdf_sha256_16
W3180479501,Connolly 2021 (BMC Neurology),2021,pilot randomized controlled crossover trial (within-subject; assessor-blinded),"Community-dwelling adults with mild-severe TBI or stroke >=3 months prior, reporting significant fatigue.",Fatigue Severity Scale (FSS) >= 4 at screening (self-reported significant fatigue).,24,home/field (in-home lighting intervention),light,"Dynamic home lighting: daytime short-wavelength-enriched high-intensity white light (CCT ~5000K) and evening short-wavelength-depleted, reduced-intensity light (<3000K) for 3h before habitual sleep time; each condition 2 months; counterbalanced order; 2-week baseline; 1-month follow-up.","control lighting condition (lower melanopic content / approx baseline home lighting; CCT ~3000-4000K), 2 months, crossover.",60,vigilance,PVT mean RT (10-min),end of each 2-month condition (mixed model treatment effect estimate),improves,"Treatment effect estimate -28.36 ms (95% CI -47.48, -9.23), t=-2.91, d=-1.75, p=.004; n=18 for PVT.",no,Self-reported average compliance 81% during treatment phase.,Primary fatigue outcome (BFI) not statistically significant; objective vigilance improved; sleep quality improved.,Design/inclusion: PDF p3 Fig1 + Participants; Intervention: PDF p3 Lighting intervention; Results: PDF p7 Outcomes + PDF p9 Table 3.,03ccaf917294cb36
W3180479501,Connolly 2021 (BMC Neurology),2021,pilot randomized controlled crossover trial (within-subject; assessor-blinded),Same as above.,FSS >= 4 at screening.,24,home/field,light,As above.,control lighting condition (crossover),60,vigilance,PVT fastest 10% RT (10-min),end of each 2-month condition (mixed model treatment effect estimate),improves,"Treatment effect estimate -15.10 ms (95% CI -25.03, -5.16), t=-2.98, d=-2.98, p=.003; n=18 for PVT.",no,Self-reported average compliance 81% during treatment phase.,Fig 3 suggests symptom changes may accrue more strongly during weeks 4-8 (not an acute-only effect).,PDF p9 Table 3; PDF p9 Fig 3; PDF p7 compliance.,03ccaf917294cb36
W3180479501,Connolly 2021 (BMC Neurology),2021,pilot randomized controlled crossover trial (within-subject; assessor-blinded),Same as above.,FSS >= 4 at screening.,24,home/field,light,As above.,control lighting condition (crossover),60,sleep_quality,PSQI global score,end of each 2-month condition (mixed model treatment effect estimate),improves,"Treatment effect estimate -0.97 (95% CI -1.62, -0.32), t=-2.92, d=-1.24, p=.004; n=24.",unclear,Self-reported average compliance 81% during treatment phase.,Subjective sleep disturbance improved; actigraphy sleep metrics did not show significant changes.,PDF p9 Table 3; PDF p7 Outcomes narrative.,03ccaf917294cb36
W3180479501,Connolly 2021 (BMC Neurology),2021,pilot randomized controlled crossover trial (within-subject; assessor-blinded),Same as above.,FSS >= 4 at screening.,24,home/field,light,As above.,control lighting condition (crossover),60,fatigue,Brief Fatigue Inventory (BFI),end of each 2-month condition (mixed model treatment effect estimate),null,"Treatment effect estimate -0.39 (95% CI -1.16, 0.39), t=-0.97, d=-0.42, p=.33; n=24.",unclear,Self-reported average compliance 81% during treatment phase.,Primary outcome not significant; authors note symptom improvement pattern may emerge later in treatment (weeks 4-8).,PDF p9 Table 3; PDF p11 Discussion/Conclusions; PDF p9 Fig 3.,03ccaf917294cb36
W3200473843,Connolly 2021 (Frontiers Neurology; case studies),2021,2 case studies; cross-over (Treatment then Control); no washout,Two community-dwelling adults with mild-severe TBI >=3 months prior and significant fatigue.,Eligibility required self-reported significant fatigue (FSS >= 4).,2,home/field,light,"5.5-month protocol: 2-week baseline, 2-month Treatment, 2-month Control, 1-month follow-up; ambient in-home lighting engineered for higher melanopic content daytime and lower melanopic content evenings; both cases allocated Treatment->Control (no washout).",Control/sham lighting approximating baseline home lighting.,60,fatigue,Brief Fatigue Inventory (BFI),"baseline, mid/end treatment, mid/end control, 1-month follow-up",mixed,Case 1 BFI: 5.67 (baseline) -> 1.56 (mid T) -> 1.00 (end T) -> 6.78 (mid C) -> 6.33 (end C) -> 7.00 (FU). Case 2 BFI: 4.33 -> 5.89 -> 2.33 -> 2.78 -> 3.89 -> 4.56 (Table 2). No inferential stats (case series).,unclear,Self-rated compliance with Treatment: 70% (Case 1) and 80% (Case 2).,Order not counterbalanced; possible time trends/carryover. Fatigue improved by end of treatment for both cases; control often worsened.,Design/eligibility: PDF p3 Design + Participants; Outcomes Table 2: PDF p6; Compliance: PDF p10.,6a9c9ccad71d46b0
W3200473843,Connolly 2021 (Frontiers Neurology; case studies),2021,2 case studies; cross-over (Treatment then Control); no washout,Same as above.,FSS >= 4.,2,home/field,light,As above.,Control/sham lighting approximating baseline.,60,vigilance,PVT mean RT (ms),"Case 2 only: baseline, mid/end treatment, mid/end control",unclear,Case 2 PVT mean RT (ms): 310.44 (baseline) -> 300.03 (mid T) -> 314.75 (end T) -> 288.65 (mid C) -> 268.51 (end C) (Table 2).,unclear,Treatment compliance 70-80% self-rated.,Objective vigilance data limited and not consistently improved during Treatment vs Control in this case series.,Outcome table: PDF p6 Table 2.,6a9c9ccad71d46b0
W1981621779,Tanaka 2011 (J Occup Health),2011,randomized crossover field study (1 month BL vs 1 month non-BL),Registered nurses (all female) working rapidly rotating shifts including night shifts.,Structural proxy: rotating shift-work with night shifts (sleep disturbance/sleepiness risk).,61,workplace/field,light,Bright light (Travelite device) exposure scheduled on workday mornings for day shifts for 1 month: 10 min/session before day shift (07:30-08:00); instructed to sit ~30-40 cm from light (eyes gently closed or reading).,Non-BL period (usual routine; no morning BL exposure).,30,vigilance,PVT mean RT (msec; 5-min),"Day-shift afternoon break (~14:00-15:00), repeated measures; subset n=11",improves,"Estimated mean RT: 264 ms (non-BL) vs 235.8 ms (BL); diff -28.2 ms (95% CI -46.2, -10.2), F(1,17.0)=11.0, p<0.01 (Table 4).",unclear,"Implementation rate ~75.2% (8.5 BL exposures per month / 11.3 day shifts); mean exposure time 7.8 min; measured ~6,666 lux at ~36 cm under study-like conditions.",PVT assessed in subset (11/61).,Intervention protocol: PDF p2-3; PVT results: PDF p6 Table 4; adherence: PDF p5-6 (implementation rate).,3198ca6b1d922a6a
W1981621779,Tanaka 2011 (J Occup Health),2011,randomized crossover field study,Same as above.,Rotating shift-work (structural proxy).,61,workplace/field,light,As above.,Non-BL period.,30,vigilance,PVT lapses (>500 ms),Day-shift afternoon break; subset n=11,improves,"Estimated lapses: 2.03 (non-BL) vs 0.84 (BL); diff -1.19 (95% CI -1.98, -0.40), F(1,17.4)=10.0, p<0.01 (Table 4).",unclear,Implementation rate ~75.2% over day shifts.,"After transformation, lapses difference p=0.055 (borderline).",PDF p6 Table 4.,3198ca6b1d922a6a
W1981621779,Tanaka 2011 (J Occup Health),2011,randomized crossover field study,Same as above.,Rotating shift-work (structural proxy).,61,workplace/field,light,As above.,Non-BL period.,30,sleepiness,Karolinska Sleepiness Scale (KSS) at 10:00 (day shift),mean across day-shift days over each month,improves,"Estimated mean difference -0.55 (95% CI -0.91, -0.20), F(1,55.6)=9.6, p<0.01 (Table 3).",unclear,Implementation rate ~75.2%.,No significant BL*order interaction reported for primary outcomes.,PDF p6 Table 3.,3198ca6b1d922a6a
W2158979070,Smith-Coggins 1997 (Acad Emerg Med),1997,prospective randomized double-blind active placebo-controlled crossover field study,Attending emergency physicians working rotating shifts with night rotations.,Structural proxy: night shiftwork / circadian disruption during night rotations.,6,workplace/field (ED),multi,"Experimental package: education + chronobiologic schedule design + countermeasures (sleep hygiene, bright light, nap, caffeine timing, etc.; Table 1). Used for 1 month. Crossover after 1-month washout.",Active placebo: jet lag diet + general sleep physiology/circadian education (1 month).,30,vigilance,PVT (10-min): median RT and lapses,multiple times during shifts; compared across conditions and across shift hours,null,PVT performance comparable regardless of intervention; neither experimental nor active placebo altered PVT (Fig 6). Median RT increased across the night shift when averaged across interventions (p=0.007).,unclear,Reported use of experimental intervention ~85% (active placebo use significantly lower; p=0.02).,Intervention improved subjective ratings but not objective vigilance vs placebo; small N limits power.,Design: PDF p4 Fig 1; Strategy set: PDF p2 Table 1; PVT results: PDF p7 Psychomotor Vigilance Task paragraph + PDF p8 Fig 6; adherence: PDF p7.,2051f4da29826679
W4211135645,Cheng 2022 (Sleep),2022,randomized order cross-over clinical trial (2 weeks total),Night shift workers (>=20y) with ICSD-3 shift work disorder confirmed by interview + 2-week sleep log; pure 8h night shifts during study.,Shift Work Disorder diagnosis (ICSD-3) with excessive sleepiness/sleep disturbance >=3 months; sleep-time misalignment confirmed by specialist.,60,field (real-life shift workers at home/work),sleep_timing,"Sleep timing schedules between night shifts: evening sleep 15:00-23:00 vs morning sleep 09:00-17:00; 1 week each; randomized order/counterbalanced; sleep at home; instructions to avoid bright light after work, avoid caffeine/nicotine, sleep dark/quiet, eat lightly.",Alternative sleep schedule (within-subject crossover).,7,vigilance,Smartphone PVT reaction time (5-min) after night shift,First night shift of each schedule (Table 2),improves,"First shift PVT RT: 0.67 s (morning sleep) vs 0.55 s (evening sleep), p=0.001; adjusted p=0.015 (Table 2). Lapses: 18.5 vs 15.4, p=0.009; adjusted p=0.115.",yes,Actigraphy worn continuously; no explicit adherence rate reported; schedules monitored via actigraphy/logs.,"Between-schedule differences attenuated after shifts 2-4 (mostly nonsignificant), suggesting time-dependent benefit strongest on first shift.",Design/inclusion: PDF p2 Design + Participants; Outcomes: PDF p4-5 Table 2; PVT description: PDF p3 Measurements.,237b59099d1f8f27
W4211135645,Cheng 2022 (Sleep),2022,randomized order cross-over clinical trial,Same as above.,Shift Work Disorder diagnosis.,60,field,sleep_timing,As above.,Alternative sleep schedule.,7,sleep_quality,PSQI weekly score,End of each 1-week schedule,improves,"PSQI: 8.3 (morning sleep) vs 6.4 (evening sleep), p<.001; adjusted p=.002 (Table 2).",unclear,Actigraphy/log based monitoring.,Evening sleep schedule associated with longer sleep duration on workdays (5.3 vs 4.8 h; p=0.006; Table 1).,PDF p4 Table 1-2.,237b59099d1f8f27
W3180479501,Connolly 2021 (BMC Neurology),2021,pilot randomized controlled crossover trial (within-subject; assessor-blinded),"Community-dwelling adults with mild-severe TBI or stroke >=3 months prior, reporting significant fatigue.",Fatigue Severity Scale (FSS) >= 4 at screening (self-reported significant fatigue).,24,home/field (in-home lighting intervention),light,"Dynamic home lighting: daytime short-wavelength-enriched high-intensity white light (CCT ~5000K) and evening short-wavelength-depleted, reduced-intensity light (<3000K) for 3h before habitual sleep time; each condition 2 months; counterbalanced order; 2-week baseline; 1-month follow-up.","control lighting condition (lower melanopic content / approx baseline home lighting; CCT ~3000-4000K), 2 months, crossover.",60,sleepiness,Epworth Sleepiness Scale (ESS),end of each 2-month condition (mixed model treatment effect estimate),null,"Treatment effect estimate 0.59 (95% CI -0.83, 2.01), t=0.82, d=0.35, p=.41; n=24.",unclear,Self-reported average compliance 81% during treatment phase.,"Direction suggests slightly higher sleepiness in Treatment vs Control, but not statistically significant.",PDF p9 Table 3.,03ccaf917294cb36
W3180479501,Connolly 2021 (BMC Neurology),2021,pilot randomized controlled crossover trial (within-subject; assessor-blinded),"Community-dwelling adults with mild-severe TBI or stroke >=3 months prior, reporting significant fatigue.",Fatigue Severity Scale (FSS) >= 4 at screening (self-reported significant fatigue).,24,home/field (in-home lighting intervention),light,"Dynamic home lighting: daytime short-wavelength-enriched high-intensity white light (CCT ~5000K) and evening short-wavelength-depleted, reduced-intensity light (<3000K) for 3h before habitual sleep time; each condition 2 months; counterbalanced order; 2-week baseline; 1-month follow-up.","control lighting condition (lower melanopic content / approx baseline home lighting; CCT ~3000-4000K), 2 months, crossover.",60,sleep_quality,Insomnia Severity Index (ISI),end of each 2-month condition (mixed model treatment effect estimate),improves,"Treatment effect estimate -2.06 (95% CI -3.99, -0.14), t=-2.06, d=-0.89, p=.036; n=24.",unclear,Self-reported average compliance 81% during treatment phase.,Subjective insomnia symptoms improved during Treatment vs Control.,PDF p9 Table 3.,03ccaf917294cb36
W1981621779,Tanaka 2011 (J Occup Health),2011,randomized crossover field study (1 month BL vs 1 month non-BL),Registered nurses (all female) working rapidly rotating shifts including night shifts.,Structural proxy: rotating shift-work with night shifts (sleep disturbance/sleepiness risk).,61,workplace/field,light,Bright light (Travelite device) exposure scheduled on workday mornings for day shifts for 1 month: 10 min/session before day shift (07:30-08:00); instructed to sit ~30-40 cm from light (eyes gently closed or reading).,Non-BL period (usual routine; no morning BL exposure).,30,fatigue,Checklist Individual Strength (CIS) fatigue,mean across day-shift days over each month,improves,"Estimated means: 75.38 (non-BL) vs 73.24 (BL); diff -2.13 (95% CI -3.78, -0.48), F(1,49.6)=6.7, p=0.01 (Table 3).",unclear,"Implementation rate ~75.2% (8.5 BL exposures per month / 11.3 day shifts); mean exposure time 7.8 min; measured ~6,666 lux at ~36 cm under study-like conditions.",CIS fatigue reflects fatigue in the previous two weeks (per authors).,PDF p6 Table 3.,3198ca6b1d922a6a
W4211135645,Cheng 2022 (Sleep),2022,randomized order cross-over clinical trial (2 weeks total),Night shift workers (>=20y) with ICSD-3 shift work disorder confirmed by interview + 2-week sleep log; pure 8h night shifts during study.,Shift Work Disorder diagnosis (ICSD-3) with excessive sleepiness/sleep disturbance >=3 months; sleep-time misalignment confirmed by specialist.,60,field (real-life shift workers at home/work),sleep_timing,"Sleep timing schedules between night shifts: evening sleep 15:00-23:00 vs morning sleep 09:00-17:00; 1 week each; randomized order/counterbalanced; sleep at home; instructions to avoid bright light after work, avoid caffeine/nicotine, sleep dark/quiet, eat lightly.",Alternative sleep schedule (within-subject crossover).,7,sleepiness,Karolinska Sleepiness Scale (KSS),"After night shift (within 1h), by shift number (Table 2)",improves,"KSS First shift: 4.9 (morning) vs 4.1 (evening), p=0.002; adjusted p=0.012. Second shift: 4.3 vs 4.0, adjusted p=0.097. Third shift: 5.1 vs 3.8, adjusted p=0.019. Fourth shift: ns (Table 2).",yes,Actigraphy worn continuously; no explicit adherence rate reported; schedules monitored via actigraphy/logs.,Sleepiness benefit persists through shift 3 in unadjusted models; attenuates by shift 4.,PDF p4-5 Table 2.,237b59099d1f8f27
W2094064988,Boudreau 2013 (PLoS ONE),2013,Randomized field intervention dataset (control vs bright light/darkness); current paper reanalyzes by circadian adaptation status (adapted vs non-adapted) with pre/post 48h lab visits.,"Healthy police officers on patrol working a fixed rotating roster including 7 consecutive night shifts (8-8.5h). Two participants completed both intervention and control conditions (counterbalanced), yielding 17 lab evaluations.",Structural proxy: rotating shift work with 7 consecutive night shifts; circadian adaptation classified by salivary melatonin acrophase during scheduled daytime sleep in post-night-shift lab visit.,"15 (17 evaluations; adapted=7 evals, non-adapted=10 evals)",field + lab (ambulatory night shifts + 48h lab visits before/after),light,Light/darkness management during 7 consecutive night shifts (prior RCT): light exposure monitored with collar sensor; intervention participants wore orange-tinted goggles from sunrise to bedtime (and if awake during daytime sleep) to attenuate circadian-effective daylight; sleep periods scheduled in total darkness; in-lab light kept very dim (<10 lux).,Adapted vs non-adapted circadian phase after the 7-night sequence (classification based on melatonin acrophase timing).,7,vigilance,"PVT median reaction speed (1/RT) (10-min), by time awake","Post-night-shift lab visit (daytime sleep schedule), across wake period",improves,"Median reaction speed: no main effect of adaptation group (p=0.88); main effect of visit (p=0.012); main effect of time awake (p=0.036); 3-way interaction (group×visit×time-awake) p=0.046. During visit 2, adapted group faster than non-adapted after 8–14h awake (p≤0.045).",unclear,Light sensor worn during ambulatory period; orange-tinted goggles required for intervention group from sunrise to bedtime (per protocol).,Analysis is primarily by adaptation status (not by randomized group); authors report adapted individuals show more stable performance across visits.,Design/participants/adaptation definition: PDF p2 (Methods Participants/Procedures/Adaptation groups); PVT analysis: PDF p5 (PVT analysis section) + Fig 3 caption on PDF p8.,81297a9484afbf60
W2094064988,Boudreau 2013 (PLoS ONE),2013,As above (adapted vs non-adapted reanalysis).,Same cohort.,Structural proxy (night shift) + adaptation status defined by melatonin acrophase timing.,15 (17 evaluations),field + lab,light,As above.,Adapted vs non-adapted.,7,sleep_quality,"PSG sleep (TST, SE, WASO) during night vs day sleep in lab","Lab visit 1 (night sleep) vs visit 2 (day sleep), 2 nights each visit",improves,"Table 1: Daytime sleep (V2) TST 449.36±5.89 min (adapted) vs 398.52±19.31 (non-adapted); SE 0.93±0.01 vs 0.83±0.04; WASO 15.28±2.49 vs 71.52±19.1. Significant visit×group interactions: TST p=0.005, SE p=0.008, WASO p=0.016; WASO lower in adapted vs non-adapted during V2 (p≤0.048) and trend for higher TST (p=0.069) reported in text.",unclear,Polysomnography recorded every sleep period in lab.,Adapted group maintained night-like sleep quality during daytime sleep; non-adapted showed deterioration during daytime sleep.,PSG results narrative: PDF p5 (PSG recordings section); Table 1: PDF p7.,81297a9484afbf60
W2094064988,Boudreau 2013 (PLoS ONE),2013,As above.,Same cohort.,Structural proxy + adaptation status.,15 (17 evaluations),field + lab,light,As above.,Adapted vs non-adapted.,7,physiology,HRV during sleep (LF:HF ratio; HF power) by sleep stage,Night sleep (V1) and day sleep (V2) PSG epochs,improves,"LF:HF ratio ~2x higher in non-adapted vs adapted during wake-in-bed (+104%, p=0.015) and REM sleep (+81%, p=0.049); trend during stage 2 (+109%, p=0.06). Trend for higher HF power in adapted vs non-adapted (p=0.06).",unclear,ECG recorded during PSG sleep periods.,Non-adaptation (circadian misalignment/sleep restriction) associated with greater sympathetic dominance during sleep.,HRV analysis: PDF p7 (HRV analysis section) + Fig 5 caption on PDF p10.,81297a9484afbf60
W2128384646,Kubo 2011 (Scand J Work Environ Health),2011,Counterbalanced within-subject crossover over 3 successive weeks (weekend sleep extension vs habitual weekend sleep).,Daytime manufacturing employees with habitual short weekday sleep (mean weekday sleep ≤6h); neither extreme morning nor evening chronotype; no prescription meds; N=26 completers.,Structural proxy: chronic weekday sleep restriction (mean weekday sleep ≤6h) in working adults.,26,field (real-life workers),sleep_timing,Weekend sleep extension: instructed to remain in bed ≥8h between 22:00–09:00 on Fri/Sat/Sun; no daytime naps; minimal support (no reminders).,"Habitual weekend sleep pattern (control weekend), counterbalanced order.",3,vigilance,PVT reaction time / reaction speed (10-min; PVT-192),Monday afternoon after the weekend (post-intervention vs post-control weekend),improves,"Significantly shorter reaction times on Mondays after the intervention vs habitual weekend sleep (p<0.05); overall condition×day interaction F(3,175)=6.01, p=0.001 (Figure 3; Table 1).",yes,Sleep monitored with actigraphy throughout; PVT practiced briefly before each test session.,Performance benefit observed early in week only; weekday sleep duration returned to short periods after intervention (Abstract/Results).,Design/protocol: PDF p3-4 (Study design/Procedure); PVT method: PDF p3 (Measurements); ANOVA: PDF p5 Table 1; Monday/Thursday pattern: PDF p7 Figure 3 + Results text on PDF p4-5.,b6fd6af11284d5a7
W2128384646,Kubo 2011 (Scand J Work Environ Health),2011,Counterbalanced within-subject crossover over 3 successive weeks (weekend sleep extension vs habitual weekend sleep).,Daytime manufacturing employees with habitual short weekday sleep (mean weekday sleep ≤6h); neither extreme morning nor evening chronotype; no prescription meds; N=26 completers.,Structural proxy: chronic weekday sleep restriction (mean weekday sleep ≤6h) in working adults.,26,field (real-life workers),sleep_timing,Weekend sleep extension: instructed to remain in bed ≥8h between 22:00–09:00 on Fri/Sat/Sun; no daytime naps; minimal support (no reminders).,"Habitual weekend sleep pattern (control weekend), counterbalanced order.",3,vigilance,PVT lapses (>500 ms) (10-min),Monday afternoon after the weekend,improves,"Fewer PVT lapses on Mondays after intervention vs habitual weekend sleep (p<0.05); overall condition×day interaction F(3,175)=4.53, p=0.004 (Figure 3; Table 1).",yes,Sleep monitored with actigraphy throughout; PVT practiced briefly before each test session.,Direction reverses by Thursday (see next row).,PDF p5 Table 1; PDF p7 Figure 3.,b6fd6af11284d5a7
W2128384646,Kubo 2011 (Scand J Work Environ Health),2011,Counterbalanced within-subject crossover over 3 successive weeks (weekend sleep extension vs habitual weekend sleep).,Daytime manufacturing employees with habitual short weekday sleep (mean weekday sleep ≤6h); neither extreme morning nor evening chronotype; no prescription meds; N=26 completers.,Structural proxy: chronic weekday sleep restriction (mean weekday sleep ≤6h) in working adults.,26,field (real-life workers),sleep_timing,Weekend sleep extension: instructed to remain in bed ≥8h between 22:00–09:00 on Fri/Sat/Sun; no daytime naps; minimal support (no reminders).,"Habitual weekend sleep pattern (control weekend), counterbalanced order.",3,vigilance,PVT reaction time / reaction speed (10-min),Thursday afternoon after the weekend,worsens,"Significantly longer reaction times on Thursdays after intervention vs habitual weekend sleep (p<0.05), despite Monday improvement; condition×day interaction F(3,175)=6.01, p=0.001 (Figure 3; Table 1).",yes,Sleep monitored with actigraphy throughout; PVT practiced briefly before each test session.,Suggests benefits are not durable across the week when weekday sleep returns to short duration.,PDF p7 Figure 3; Results text on PDF p5.,b6fd6af11284d5a7
W2128384646,Kubo 2011 (Scand J Work Environ Health),2011,Counterbalanced within-subject crossover over 3 successive weeks (weekend sleep extension vs habitual weekend sleep).,Daytime manufacturing employees with habitual short weekday sleep (mean weekday sleep ≤6h); neither extreme morning nor evening chronotype; no prescription meds; N=26 completers.,Structural proxy: chronic weekday sleep restriction (mean weekday sleep ≤6h) in working adults.,26,field (real-life workers),sleep_timing,Weekend sleep extension: instructed to remain in bed ≥8h between 22:00–09:00 on Fri/Sat/Sun; no daytime naps; minimal support (no reminders).,"Habitual weekend sleep pattern (control weekend), counterbalanced order.",3,vigilance,PVT lapses (>500 ms) (10-min),Thursday afternoon after the weekend,worsens,"Significantly more lapses on Thursdays after intervention vs habitual weekend sleep (p<0.05); condition×day interaction F(3,175)=4.53, p=0.004 (Figure 3; Table 1).",yes,Sleep monitored with actigraphy throughout; PVT practiced briefly before each test session.,"Net effect across week is mixed (Monday benefit, Thursday impairment).",PDF p7 Figure 3; PDF p5 Table 1.,b6fd6af11284d5a7
W2165853793,Bjorvatn 2007 (Scand J Work Environ Health),2007,Randomized placebo-controlled crossover field study across 3 consecutive 14-day swing-shift schedules (placebo vs melatonin vs bright light).,"Oil rig workers in the North Sea on swing shifts (week 1 nights, week 2 days). Included workers reporting shift-work adjustment problems (>3 days to adapt/readapt or sleep problem rating > moderate). N=17 completers.",Structural + symptom proxy: swing-shift night work with reported adaptation problems (sleepiness/sleep complaints).,17,field (oil rig workplace),melatonin,Melatonin 3 mg capsule taken 1h before bedtime during first 4 days of night-shift week and first 4 days of day-shift week (double-blind vs placebo capsule).,Placebo capsule (crossover).,4,sleep_quality,Sleep diary total sleep time (minutes),"Night-shift week (first week), excluding swing day",improves,Night shift TST: placebo 386±53 vs melatonin 405±47 min; effect size vs placebo d=0.38; melatonin significantly > placebo (p=0.047) (Table 4).,unclear,Capsules administered blind; daily sleep diary recorded across 14 days; one participant excluded from diary analyses for poor compliance.,Authors summarize melatonin increased sleep by ~15–20 min/day and modestly reduced sleepiness during day shift.,Methods (protocol): PDF p3-4; Table 4: PDF p7; narrative: PDF p7.,cb7b6ed2be011f56
W2165853793,Bjorvatn 2007 (Scand J Work Environ Health),2007,Randomized placebo-controlled crossover field study.,Same cohort.,Swing-shift night work + adaptation problems.,17,field,light,"Bright light: 30-min daily exposure using 10,000-lux light box (50 cm) during first 4 nights of night-shift week and first 4 days of day-shift week; timing individually scheduled and delayed by ~1h/day to phase delay; instructed to avoid bright light after exposure.",Placebo capsule condition (cross-over baseline) for effect size reference.,4,sleep_quality,Sleep diary sleep onset latency (minutes),"Night-shift week (first week), excluding swing day",improves,Night shift SOL: placebo 14±9 vs bright light 9±5 min; effect size vs placebo d=0.69; bright light significantly < placebo (p=0.030) and < melatonin (p=0.023) (Table 4).,unclear,30-min sessions scheduled individually; no rig light-level recordings in this study (authors note earlier measurements ~200–300 lux average).,Bright light effects generally intermediate between melatonin and placebo on subjective sleepiness measures; limited significant results.,Bright light protocol: PDF p4; Table 4: PDF p7.,cb7b6ed2be011f56
W2165853793,Bjorvatn 2007 (Scand J Work Environ Health),2007,Randomized placebo-controlled crossover field study.,Same cohort.,Swing-shift + adaptation problems.,17,field,melatonin,Melatonin 3 mg 1h pre-bedtime (first 4 days of each shift week).,Placebo (crossover).,4,sleepiness,ATS: Fighting sleep (%) during day shift week,"Day-shift week (second week), averaged across week",improves,Day shift fighting sleep: placebo 3.4±3.5 vs melatonin 1.8±2.8; effect size vs placebo d=0.50; melatonin significantly lower than placebo (p=0.021) and bright light (p=0.022) (Table 3).,unclear,Daily ATS ratings recorded before bed across 14 days.,Subjective sleepiness benefits of melatonin were more evident during day work than night work (per authors).,ATS/subjective sleepiness: PDF p4 (Subjective measures) + Table 3 on PDF p6.,cb7b6ed2be011f56
W2165853793,Bjorvatn 2007 (Scand J Work Environ Health),2007,Randomized placebo-controlled crossover field study.,Same cohort.,Swing-shift + adaptation problems.,17,field,melatonin,Melatonin 3 mg 1h pre-bedtime.,Placebo.,4,sleepiness,Quality of day rating (1 very good to 9 very bad) during day shift week,"Day-shift week (second week), averaged across week",improves,Quality of day (day shift): placebo 4.1±1.1 vs melatonin 3.4±0.6; effect size vs placebo d=0.79; melatonin significantly better than placebo (p=0.041) (Table 3).,unclear,Daily rating recorded.,"KSS day-shift mean was lower with melatonin (3.9 vs 4.3), but overall condition main effect for KSS day shift not significant (p=0.087); effects varied by day (condition×day p=0.001) (Table 1).",Table 3: PDF p6; ANOVA summary: PDF p5 Table 1.,cb7b6ed2be011f56
W2165853793,Bjorvatn 2007 (Scand J Work Environ Health),2007,Randomized placebo-controlled crossover field study.,Same cohort.,Swing-shift + adaptation problems.,17,field,melatonin/light,Melatonin or bright light during first 4 days of shift weeks.,Placebo baseline.,4,vigilance,Objective 5-min serial reaction-time test (Palm) at 3 timepoints during shifts,"Nights 1,3,6 and days 1,3,6",unclear,"No significant differences in reaction times when averaged across night shift or day shift. Day shift showed condition×day interaction F(4,44)=4.1, p=0.025 (Table 1), driven by increased reaction times on day 1 after melatonin and bright light (narrative; Figure 4).",unclear,"Reaction-time tests performed at prespecified shift times (00:00/03:00/06:00 nights 1,3,6; 12:00/15:00/18:00 days 1,3,6).",Objective performance effects were small in this field setting relative to simulated studies (authors’ conclusion).,Objective measures: PDF p4; ANOVA: PDF p5 Table 1; narrative + Figure 4: PDF p8.,cb7b6ed2be011f56
W2494879164,Pagar 2016 (IOSR-JDMS),2016,"Within-subject pre/post caffeine challenge at baseline, then re-tested after ~6 months daily coffee; no placebo; unblinded.","Healthy adults (20-25y), 30 male + 30 female; baseline self-reported caffeine intake <200 mg/day; excluded major illness, smoking/alcohol, sensory deficits.",General healthy adults; not selected for low baseline arousal. Baseline session required >=24h caffeine abstinence.,60,lab (controlled room; 4-6 pm testing),caffeine,"Acute: ~250 mg caffeine (1 cup coffee), reaction time measured pre-dose and 30 min post-dose. Chronic: instructed 2-5 cups/day for 6 months (200-600 mg/day; diary).",Within-subject pre-dose baseline; baseline (non-habitual) vs after 6 months habitual moderate use.,1,vigilance,"Visual reaction time (ms), red stimulus (VRT-R)","Baseline (non-habitual; >=24h abstinent), 30 min post ~250 mg caffeine",improves,Males: 210.50±3.27 -> 202.80±3.02 ms (p<0.01). Females: 216.50±2.87 -> 208.30±2.06 ms (p<0.001).,no,Baseline abstinence instructed; no biomarker. Practice sessions (10) before testing.,Acute caffeine improves simple RT in non-habitual state.,Methods: PDF p2 (Material and Method; timing); Results: PDF p2 Table 1 (males) + PDF p3 Table 2 (females).,4464a7b2d6d64ab3
W2494879164,Pagar 2016 (IOSR-JDMS),2016,"Within-subject pre/post caffeine challenge at baseline, then re-tested after ~6 months daily coffee; no placebo; unblinded.","Healthy adults (20-25y), 30 male + 30 female; baseline self-reported caffeine intake <200 mg/day; excluded major illness, smoking/alcohol, sensory deficits.",General healthy adults; not selected for low baseline arousal. Baseline session required >=24h caffeine abstinence.,60,lab (controlled room; 4-6 pm testing),caffeine,"Acute: ~250 mg caffeine (1 cup coffee), reaction time measured pre-dose and 30 min post-dose. Chronic: instructed 2-5 cups/day for 6 months (200-600 mg/day; diary).",Within-subject pre-dose baseline; baseline (non-habitual) vs after 6 months habitual moderate use.,1,vigilance,"Auditory reaction time (ms), high pitched stimulus (ART-H)","Baseline (non-habitual; >=24h abstinent), 30 min post ~250 mg caffeine",improves,Males: 194.63±1.73 -> 184.43±1.97 ms (p<0.001). Females: 200.60±3.02 -> 191.50±3.00 ms (p<0.001).,no,Baseline abstinence instructed; no biomarker.,Auditory RT improves; absolute effects modest.,Results: PDF p2 Table 1 (males) + PDF p3 Table 2 (females).,4464a7b2d6d64ab3
W2494879164,Pagar 2016 (IOSR-JDMS),2016,"Within-subject pre/post caffeine challenge at baseline, then re-tested after ~6 months daily coffee; no placebo; unblinded.","Healthy adults (20-25y), 30 male + 30 female; baseline self-reported caffeine intake <200 mg/day; excluded major illness, smoking/alcohol, sensory deficits.",General healthy adults; not selected for low baseline arousal. Baseline session required >=24h caffeine abstinence.,60,lab (controlled room; 4-6 pm testing),caffeine,"Acute: ~250 mg caffeine (1 cup coffee), reaction time measured pre-dose and 30 min post-dose. Chronic: instructed 2-5 cups/day for 6 months (200-600 mg/day; diary).",Within-subject pre-dose baseline; baseline (non-habitual) vs after 6 months habitual moderate use.,180,vigilance,"Visual reaction time (ms), red stimulus (VRT-R)","After ~6 months daily coffee (200-600 mg/day), 30 min post ~250 mg caffeine",improves,Males: 203.03±1.84 -> 197.16±2.10 ms (p<0.05). Females: 211.80±1.68 -> 205.96±2.10 ms (p<0.05).,yes,Caffeine diary; no assay. Testing scheduled 8-10h after normal caffeine consumption to reduce additive/withdrawal effects (per authors).,Acute effect persists but is smaller than baseline non-habitual session (tolerance / ceiling).,Methods: PDF p2 (6-month diary + timing rationale). Results: PDF p3 Table 5 (males) + PDF p3 Table 6 (females).,4464a7b2d6d64ab3
W2494879164,Pagar 2016 (IOSR-JDMS),2016,"Within-subject pre/post caffeine challenge at baseline, then re-tested after ~6 months daily coffee; no placebo; unblinded.","Healthy adults (20-25y), 30 male + 30 female; baseline self-reported caffeine intake <200 mg/day; excluded major illness, smoking/alcohol, sensory deficits.",General healthy adults; not selected for low baseline arousal. Baseline session required >=24h caffeine abstinence.,60,lab (controlled room; 4-6 pm testing),caffeine,"Acute: ~250 mg caffeine (1 cup coffee), reaction time measured pre-dose and 30 min post-dose. Chronic: instructed 2-5 cups/day for 6 months (200-600 mg/day; diary).",Within-subject pre-dose baseline; baseline (non-habitual) vs after 6 months habitual moderate use.,180,vigilance,"Auditory reaction time (ms), high pitched stimulus (ART-H)","After ~6 months daily coffee (200-600 mg/day), 30 min post ~250 mg caffeine",improves,Males: 188.50±1.71 -> 182.66±1.86 ms (p<0.02). Females: 196.93±3.40 -> 190.80±3.45 ms (p<0.02).,yes,Diary-based habitual intake only.,Reduced acute delta vs baseline suggests partial tolerance.,Results: PDF p3 Table 5 (males) + PDF p3 Table 6 (females).,4464a7b2d6d64ab3
W1496048461,Watson 2002 (Br J Clin Pharmacol),2002,Randomized double-blind placebo-controlled crossover: 200 mg caffeine capsules vs placebo twice daily for 7 days; acute 200 mg caffeine challenge on test day with repeated measures over 120 min.,"Healthy volunteers (n=12 randomized; prior regular caffeine consumers per authors), fasting overnight; studied in metabolism research unit.",General healthy adults; not selected for low arousal. Overnight fast + controlled lab setting; withdrawal confounding minimized by design but not eliminated.,12,lab/clinical research unit,caffeine,Caffeine-replete: 200 mg caffeine capsule twice daily for 7 days. Caffeine-naive: placebo capsules with caffeine-free diet for 7 days. On test day: decaf coffee containing 200 mg caffeine; outcomes measured q30 min for 120 min.,Caffeine-replete vs caffeine-naive (placebo) condition (within-subject crossover).,7,vigilance,"Four-choice reaction time (4CRT), 5-min portable test",Post acute caffeine challenge (0-120 min summary),improves,4CRT improved by 0.02±0.01 s after caffeine in both caffeine-naive and caffeine-replete conditions; no between-condition difference reported (authors: cognitive performance not affected by prior exposure).,no,Capsules double-blind; caffeine-free diet instructed; glucose maintained >4.0 mmol/L during visits.,No evidence of tolerance in 4CRT under this protocol; VCD/VMD also showed no caffeine-related improvements.,"4CRT method: PDF p2 (Experimental procedure, baseline measures). 4CRT result statement: PDF p4 (Psychometric tests / Discussion).",1124372f74af0f95
W1496048461,Watson 2002 (Br J Clin Pharmacol),2002,Randomized double-blind placebo-controlled crossover: 200 mg caffeine capsules vs placebo twice daily for 7 days; acute 200 mg caffeine challenge on test day with repeated measures over 120 min.,"Healthy volunteers (n=12 randomized; prior regular caffeine consumers per authors), fasting overnight; studied in metabolism research unit.",General healthy adults; not selected for low arousal. Overnight fast + controlled lab setting; withdrawal confounding minimized by design but not eliminated.,12,lab/clinical research unit,caffeine,Caffeine-replete: 200 mg caffeine capsule twice daily for 7 days. Caffeine-naive: placebo capsules with caffeine-free diet for 7 days. On test day: decaf coffee containing 200 mg caffeine; outcomes measured q30 min for 120 min.,Caffeine-replete vs caffeine-naive (placebo) condition (within-subject crossover).,7,physiology,Middle cerebral artery blood velocity (VMCA) change (cm/s) after acute caffeine,0-120 min post acute caffeine (summary measures),unclear,"VMCA decreased in both conditions, larger in caffeine-naive vs caffeine-replete: -8.0 [-10.0, -6.1] vs -4.9 [-6.8, -2.9] cm/s; P<0.02.",yes,Transcranial Doppler recorded supine; protocol controlled; crossover with >=2-week gap.,Central vascular response shows partial tolerance after 1 week sustained caffeine.,Abstract: PDF p1 Results. Detailed results: PDF p3 (Haemodynamics) + Figure 1.,1124372f74af0f95
W1496048461,Watson 2002 (Br J Clin Pharmacol),2002,Randomized double-blind placebo-controlled crossover: 200 mg caffeine capsules vs placebo twice daily for 7 days; acute 200 mg caffeine challenge on test day with repeated measures over 120 min.,"Healthy volunteers (n=12 randomized; prior regular caffeine consumers per authors), fasting overnight; studied in metabolism research unit.",General healthy adults; not selected for low arousal. Overnight fast + controlled lab setting; withdrawal confounding minimized by design but not eliminated.,12,lab/clinical research unit,caffeine,Caffeine-replete: 200 mg caffeine capsule twice daily for 7 days. Caffeine-naive: placebo capsules with caffeine-free diet for 7 days. On test day: decaf coffee containing 200 mg caffeine; outcomes measured q30 min for 120 min.,Caffeine-replete vs caffeine-naive (placebo) condition (within-subject crossover).,7,physiology,Blood pressure response after acute caffeine (systolic/diastolic),0-120 min post acute caffeine,unclear,"Systolic BP rise not significantly different at peak (+8.7 [2.1,13.4] vs +4.5 [0.8,8.3] mmHg; p=0.13) but more sustained in caffeine-naive (AUC difference p<0.04). Diastolic rise greater in caffeine-naive (+5.5 [3.2,8.6] vs +1.1 [-0.8,3.0] mmHg; P<0.005); AUC p=0.055.",yes,Automated BP; repeated measures q30 min; euglycaemia maintained.,Peripheral pressor response shows partial tolerance (attenuation) but not complete.,Abstract: PDF p1 Results. Detailed results: PDF p3 (Haemodynamics) + Figure 2.,1124372f74af0f95
W1496048461,Watson 2002 (Br J Clin Pharmacol),2002,Randomized double-blind placebo-controlled crossover: 200 mg caffeine capsules vs placebo twice daily for 7 days; acute 200 mg caffeine challenge on test day with repeated measures over 120 min.,"Healthy volunteers (n=12 randomized; prior regular caffeine consumers per authors), fasting overnight; studied in metabolism research unit.",General healthy adults; not selected for low arousal. Overnight fast + controlled lab setting; withdrawal confounding minimized by design but not eliminated.,12,lab/clinical research unit,caffeine,Caffeine-replete: 200 mg caffeine capsule twice daily for 7 days. Caffeine-naive: placebo capsules with caffeine-free diet for 7 days. On test day: decaf coffee containing 200 mg caffeine; outcomes measured q30 min for 120 min.,Caffeine-replete vs caffeine-naive (placebo) condition (within-subject crossover).,7,other,UWIST tense mood score (0-32),Baseline + post acute caffeine (max/min response),mixed,"Baseline tense mood higher in caffeine-replete vs caffeine-naive: 16.3±1.6 vs 11.6±0.6 (P<0.01). Tense mood decreased more after caffeine in caffeine-replete: -4.7 [-7.5,-1.9] vs -1.1 [-2.6,-0.34] (P<0.02).",yes,UWIST mood checklist administered at baseline and serially.,Pattern consistent with withdrawal-reversal or chronic caffeine-related tension at baseline.,Results: PDF p3 (Symptom score) + Figure 3 (mood).,1124372f74af0f95
W2946071698,Weibel 2019 (bioRxiv preprint),2019,"Double-blind within-subject crossover with 3 conditions (caffeine vs placebo vs withdrawal), each 10 days; 43h controlled lab protocol starting day 9.",Young healthy male habitual caffeine consumers (habitual intake 300-600 mg/day) screened for good sleep quality (PSQI<=5) and non-extreme chronotype; n=20 completed.,General adults; not selected for low arousal. Withdrawal condition induces low arousal state (sleepiness + lapses).,20,"ambulatory (9 days) + controlled lab (43h, <8 lux)",caffeine,"Caffeine condition: 150 mg caffeine capsule 3x/day (+45, +255, +475 min after wake) for 10 days. Placebo: mannitol capsules 3x/day for 10 days. Withdrawal: caffeine 3x/day until day 9 late morning then switch to placebo; assessments during lab stay.",Placebo vs caffeine vs withdrawal (within-subject).,10,sleepiness,"Karolinska Sleepiness Scale (KSS), binned to 4h intervals",Day+night during 43h lab protocol (mixed model),mixed,"Withdrawal higher sleepiness vs placebo/caffeine: main effect condition F(2,58)=9.71, p<0.001; mean±SD placebo 4.72±1.78, caffeine 4.66±1.91, withdrawal 5.27±1.81; post-hoc withdrawal>both p<0.01.",yes,Compliance verified via caffeine metabolites in fingertip sweat; fixed sleep-wake schedule monitored by actigraphy.,"After 10-day repeated caffeine, subjective sleepiness not improved vs placebo; withdrawal shows clear low-arousal signal.",KSS method: PDF p7 (Neurobehavioral assessments). Results: PDF p10 (Subjective Sleepiness).,7388813e605cab47
W2946071698,Weibel 2019 (bioRxiv preprint),2019,"Double-blind within-subject crossover with 3 conditions (caffeine vs placebo vs withdrawal), each 10 days; 43h controlled lab protocol starting day 9.",Young healthy male habitual caffeine consumers (habitual intake 300-600 mg/day) screened for good sleep quality (PSQI<=5) and non-extreme chronotype; n=20 completed.,General adults; not selected for low arousal. Withdrawal condition induces low arousal state (sleepiness + lapses).,20,"ambulatory (9 days) + controlled lab (43h, <8 lux)",caffeine,"Caffeine condition: 150 mg caffeine capsule 3x/day (+45, +255, +475 min after wake) for 10 days. Placebo: mannitol capsules 3x/day for 10 days. Withdrawal: caffeine 3x/day until day 9 late morning then switch to placebo; assessments during lab stay.",Placebo vs caffeine vs withdrawal (within-subject).,10,vigilance,"PVT (10-min): lapses (RT>500 ms), z-transformed",Day+night during 43h lab protocol (mixed model),mixed,"More lapses during withdrawal vs placebo/caffeine: main effect condition F(2,51)=6.66, p=0.0027; mean±SD (z) placebo -0.18±0.77, caffeine -0.09±1.04, withdrawal 0.27±1.11; post-hoc withdrawal>both p<0.01.",yes,Same as above; one participant excluded in caffeine condition for incompliance (per authors).,Objective vigilance not improved in caffeine vs placebo after repeated intake; withdrawal impairs vigilance.,PVT method: PDF p7 (Neurobehavioral assessments). Results: PDF p10 (Vigilance Performance).,7388813e605cab47
W2946071698,Weibel 2019 (bioRxiv preprint),2019,"Double-blind within-subject crossover with 3 conditions (caffeine vs placebo vs withdrawal), each 10 days; 43h controlled lab protocol starting day 9.",Young healthy male habitual caffeine consumers (habitual intake 300-600 mg/day) screened for good sleep quality (PSQI<=5) and non-extreme chronotype; n=20 completed.,General adults; not selected for low arousal. Withdrawal condition induces low arousal state (sleepiness + lapses).,20,"ambulatory (9 days) + controlled lab (43h, <8 lux)",caffeine,"Caffeine condition: 150 mg caffeine capsule 3x/day (+45, +255, +475 min after wake) for 10 days. Placebo: mannitol capsules 3x/day for 10 days. Withdrawal: caffeine 3x/day until day 9 late morning then switch to placebo; assessments during lab stay.",Placebo vs caffeine vs withdrawal (within-subject).,10,sleep_quality,"Evening nap PSG: TST, SWS, SE, sleep latencies",Evening nap during lab protocol (Table 1),mixed,Withdrawal shows higher sleep propensity vs placebo/caffeine: Table 1 TST 43.88±2.83 vs 31.63±3.90 (placebo) and 24.26±4.55 (caffeine); SE 73.12±4.72 vs 52.71±6.50 and 40.44±7.58; condition effects p<0.001. SL1 12.09±2.11 vs 25.70±3.94 and 28.51±4.57; p=0.002.,yes,Polysomnography during scheduled nap; controlled light/posture/meals.,Withdrawal increases sleep drive even during high circadian wake-promotion window.,Nap results narrative: PDF p11. Table 1: PDF p24.,7388813e605cab47
W2946071698,Weibel 2019 (bioRxiv preprint),2019,"Double-blind within-subject crossover with 3 conditions (caffeine vs placebo vs withdrawal), each 10 days; 43h controlled lab protocol starting day 9.",Young healthy male habitual caffeine consumers (habitual intake 300-600 mg/day) screened for good sleep quality (PSQI<=5) and non-extreme chronotype; n=20 completed.,General adults; not selected for low arousal. Withdrawal condition induces low arousal state (sleepiness + lapses).,20,"ambulatory (9 days) + controlled lab (43h, <8 lux)",caffeine,"Caffeine condition: 150 mg caffeine capsule 3x/day (+45, +255, +475 min after wake) for 10 days. Placebo: mannitol capsules 3x/day for 10 days. Withdrawal: caffeine 3x/day until day 9 late morning then switch to placebo; assessments during lab stay.",Placebo vs caffeine vs withdrawal (within-subject).,10,physiology,Circadian timing markers: melatonin (DLMOnset/DLMOffset) and cortisol,Lab protocol (melatonin/cortisol curves),null,"No significant condition effects on melatonin or cortisol: DLMOnset F(2,33)=1.16 p=0.325; DLMOffset F(2,35)=1.32 p=0.280; cortisol condition F(2,129)=0.43 p=0.653.",no,Saliva sampling q30-60 min; controlled dim light.,Repeated daytime caffeine intake did not measurably shift circadian phase under entrained conditions in this sample.,Results: PDF p10 (Melatonin and Cortisol). Methods: PDF p7 (Salivary melatonin and cortisol).,7388813e605cab47
W3068855346,Sunde 2020 (Frontiers in Psychology),2020,"Counterbalanced crossover with 2 study periods (7000K vs 2500K light), separated by 4 weeks; each period had 3 consecutive simulated night shifts with repeated measures across shifts and time-of-night.",Healthy adults (19-30y; mainly students) screened for sleep/health; final dataset n=30 (10 male) with some missing per condition.,Experimentally induced low arousal via simulated night work (23:00-06:45) across 3 consecutive nights; caffeine abstinence required.,30,lab (night shifts) + home (day sleep),light,"Polychromatic full-spectrum light at ~200 lx eye level during night shifts; 7000K (blue-enriched) vs 2500K (blue-depleted), with similar photon flux; testing at 23:30, 01:00, 02:30, 04:00, 05:30 each shift.",2500K lighting condition (within-subject crossover).,3,sleepiness,Karolinska Sleepiness Scale (KSS; 1-9),Across 3 simulated night shifts (mixed models; Table 3),improves,"Lower sleepiness in 7000K vs 2500K: EMM 6.15 (SE 0.16) vs 6.32 (SE 0.16); light main effect F(1,834)=4.58, p=0.033; no significant interactions.",no,Night-shift protocol monitored in lab; noise-canceling headsets; standardized snacks; caffeine abstinence 1 week prior and during (per protocol).,Effect size small; subjective alertness improves but objective PVT mean 1/RT shows no light main effect (p=0.090).,KSS method: PDF p5 (Alertness and Performance Measures). Results: PDF p7 (KSS) + Table 3 (PDF p9).,cf740867e19b81de
W3068855346,Sunde 2020 (Frontiers in Psychology),2020,"Counterbalanced crossover with 2 study periods (7000K vs 2500K light), separated by 4 weeks; each period had 3 consecutive simulated night shifts with repeated measures across shifts and time-of-night.",Healthy adults (19-30y; mainly students) screened for sleep/health; final dataset n=30 (10 male) with some missing per condition.,Experimentally induced low arousal via simulated night work (23:00-06:45) across 3 consecutive nights; caffeine abstinence required.,30,lab (night shifts) + home (day sleep),light,"Polychromatic full-spectrum light at ~200 lx eye level during night shifts; 7000K (blue-enriched) vs 2500K (blue-depleted), with similar photon flux; testing at 23:30, 01:00, 02:30, 04:00, 05:30 each shift.",2500K lighting condition (within-subject crossover).,3,vigilance,PVT (10-min): fastest 10% reaction time (ms),Across shifts; light×time interaction,mixed,"No light main effect overall (EMM 257.99 vs 259.24 ms; p=0.283), but light×time interaction significant: F(4,807)=2.91, p=0.021; post-hoc differences at later night timepoints (Figure 4; stars at ~04:00 and 05:30).",unclear,As above.,Suggests time-of-night specific benefit rather than uniform improvement.,PVT method: PDF p5. Results narrative: PDF p7 (fastest 10% RT) + Table 3 (PDF p9) + Figure 4 (PDF p9).,cf740867e19b81de
W3068855346,Sunde 2020 (Frontiers in Psychology),2020,"Counterbalanced crossover with 2 study periods (7000K vs 2500K light), separated by 4 weeks; each period had 3 consecutive simulated night shifts with repeated measures across shifts and time-of-night.",Healthy adults (19-30y; mainly students) screened for sleep/health; final dataset n=30 (10 male) with some missing per condition.,Experimentally induced low arousal via simulated night work (23:00-06:45) across 3 consecutive nights; caffeine abstinence required.,30,lab (night shifts) + home (day sleep),light,"Polychromatic full-spectrum light at ~200 lx eye level during night shifts; 7000K (blue-enriched) vs 2500K (blue-depleted), with similar photon flux; testing at 23:30, 01:00, 02:30, 04:00, 05:30 each shift.",2500K lighting condition (within-subject crossover).,3,vigilance,PVT false starts (count per bout),Late night (05:30) during shifts,improves,"Light×time effect: fewer false starts at 05:30 with 7000K vs 2500K: EMM 3.33 (SE 0.57) vs 4.83 (SE 0.93), p=0.040 (reported in results; Figure 3D).",unclear,As above.,Objective measure indicates selective late-night benefit.,Results: PDF p7 (false starts paragraph) + Figure 3D (PDF p8) + Table 3 (PDF p9).,cf740867e19b81de
W3068855346,Sunde 2020 (Frontiers in Psychology),2020,"Counterbalanced crossover with 2 study periods (7000K vs 2500K light), separated by 4 weeks; each period had 3 consecutive simulated night shifts with repeated measures across shifts and time-of-night.",Healthy adults (19-30y; mainly students) screened for sleep/health; final dataset n=30 (10 male) with some missing per condition.,Experimentally induced low arousal via simulated night work (23:00-06:45) across 3 consecutive nights; caffeine abstinence required.,30,lab (night shifts) + home (day sleep),light,"Polychromatic full-spectrum light at ~200 lx eye level during night shifts; 7000K (blue-enriched) vs 2500K (blue-depleted), with similar photon flux; testing at 23:30, 01:00, 02:30, 04:00, 05:30 each shift.",2500K lighting condition (within-subject crossover).,3,other,Digit Symbol Substitution Test (DSST): number correct,Across shifts (Table 3),improves,"More correct responses in 7000K vs 2500K: EMM 81.35 (SE 1.14) vs 80.50 (SE 1.14); light main effect F(1,816)=4.82, p=0.028.",no,As above.,Small absolute difference; learning effects possible despite practice/randomization.,DSST method: PDF p5. Results: PDF p8 (DSST) + Table 3 (PDF p9).,cf740867e19b81de
W3040483795,Domagalik 2020 (Frontiers in Neuroscience),2020,Parallel-group randomized trial: blue-light-blocking (amber) contact lenses vs normal lenses for 4 weeks; weekly lab testing; 1-week follow-up after lens removal for PVT.,"Healthy young adults with myopia and contact-lens experience; excluded poor sleep quality (PSQI>6), daytime sleepiness (ESS>10), extreme chronotypes. Completed study n=38 (19 BLB, 19 control) for PVT analysis.",Not low arousal; participants screened to exclude elevated sleepiness and poor sleep quality.,38,field (24h lens wear) + lab testing (weekly evenings),light,Blue-light-blocking group wore amber contact lenses reducing blue transmittance ~90% continuously for 4 weeks; control wore regular contact lenses. Weekly sessions included 5-min PVT; follow-up 1 week after stopping BLB lenses.,Control contact lenses group (parallel).,28,vigilance,PVT (5-min): mean reaction time (ms),Baseline + weeks 1-4; plus 1-week follow-up,worsens,"Group×session interaction: mean RT F(4,144)=2.59, p<0.05, partial η²=0.07 (increase across weeks only in BLB). Follow-up (BLB only): baseline vs week4 vs follow-up F(2,36)=21.79, p<0.001, partial η²=0.55; baseline vs follow-up ns (reversible).",no,Lens wear monitored by weekly interview; actigraphy worn (subset had circadian analysis).,Progressive slowing with prolonged blue-light reduction; reverses after returning to normal light.,Protocol/tasks: PDF p3-5 (Experimental Protocol; PVT description). Results: PDF p6 (PVT analyses) + Figure 4/5 (PDF p7-8).,6aa7a93ebac8a3ca
W3040483795,Domagalik 2020 (Frontiers in Neuroscience),2020,Parallel-group randomized trial: blue-light-blocking (amber) contact lenses vs normal lenses for 4 weeks; weekly lab testing; 1-week follow-up after lens removal for PVT.,"Healthy young adults with myopia and contact-lens experience; excluded poor sleep quality (PSQI>6), daytime sleepiness (ESS>10), extreme chronotypes. Completed study n=38 (19 BLB, 19 control) for PVT analysis.",Not low arousal; participants screened to exclude elevated sleepiness and poor sleep quality.,38,field (24h lens wear) + lab testing (weekly evenings),light,Blue-light-blocking group wore amber contact lenses reducing blue transmittance ~90% continuously for 4 weeks; control wore regular contact lenses. Weekly sessions included 5-min PVT; follow-up 1 week after stopping BLB lenses.,Control contact lenses group (parallel).,28,vigilance,PVT (5-min): omission errors (RT>=500 ms) (%),Baseline vs week4 vs follow-up (BLB only),worsens,"Baseline-weekly group×session for omissions not significant (p=0.25), but BLB baseline vs week4 vs follow-up differed: omission errors F(2,36)=5.15, p<0.05, partial η²=0.22 (post-hoc: baseline vs week4 and week4 vs follow-up significant; baseline vs follow-up ns).",no,As above.,Omissions increase at end of 4-week BLB and recover at follow-up.,Results: PDF p6 (PVT follow-up comparison) + Figure 5 (PDF p8).,6aa7a93ebac8a3ca
W3040483795,Domagalik 2020 (Frontiers in Neuroscience),2020,Parallel-group randomized trial: blue-light-blocking (amber) contact lenses vs normal lenses for 4 weeks; weekly lab testing; 1-week follow-up after lens removal for PVT.,"Healthy young adults with myopia and contact-lens experience; excluded poor sleep quality (PSQI>6), daytime sleepiness (ESS>10), extreme chronotypes. Completed study n=38 (19 BLB, 19 control) for PVT analysis.",Not low arousal; participants screened to exclude elevated sleepiness and poor sleep quality.,38,field (24h lens wear) + lab testing (weekly evenings),light,Blue-light-blocking group wore amber contact lenses reducing blue transmittance ~90% continuously for 4 weeks; control wore regular contact lenses. Weekly sessions included 5-min PVT; follow-up 1 week after stopping BLB lenses.,Control contact lenses group (parallel).,28,sleepiness,Epworth Sleepiness Scale (ESS) and PSQI,Weekly during intervention; PSQI baseline and last session,null,"No group×session interaction: ESS F(4,144)=1.72, p=0.15; PSQI F(1,36)=0.12, p=0.73. Follow-up ESS effect ns (p=0.12).",no,Questionnaires administered each session.,Subjective sleepiness did not change despite progressive PVT slowing.,Results: PDF p7 (ESS/PSQI). Participants/exclusion: PDF p3 (Participants).,6aa7a93ebac8a3ca
W3040483795,Domagalik 2020 (Frontiers in Neuroscience),2020,Parallel-group randomized trial: blue-light-blocking (amber) contact lenses vs normal lenses for 4 weeks; weekly lab testing; 1-week follow-up after lens removal for PVT.,"Healthy young adults with myopia and contact-lens experience; excluded poor sleep quality (PSQI>6), daytime sleepiness (ESS>10), extreme chronotypes. Completed study n=38 (19 BLB, 19 control) for PVT analysis.",Not low arousal; participants screened to exclude elevated sleepiness and poor sleep quality.,38,field (24h lens wear) + lab testing (weekly evenings),light,Blue-light-blocking group wore amber contact lenses reducing blue transmittance ~90% continuously for 4 weeks; control wore regular contact lenses. Weekly sessions included 5-min PVT; follow-up 1 week after stopping BLB lenses.,Control contact lenses group (parallel).,28,physiology,Melatonin (evening level; DLMO) and cortisol awakening response (CAR),Baseline vs session 2 vs session 4 (BLB group only),null,"No session effect in BLB group: mean evening melatonin F(2,36)=1.99 p=0.15; DLMO F(2,26)=1.68 p=0.21; cortisol CAR F(2,34)=1.72 p=0.20.",no,Saliva samples collected per protocol (dim light for melatonin sampling).,No evidence that 4-week blue-light reduction altered circadian hormonal markers in this sample.,Methods: PDF p4 (saliva sampling). Results: PDF p7 (melatonin/cortisol) + Figure 7.,6aa7a93ebac8a3ca
W4285731316,Kjorstad 2022 (BMC Nursing),2022,non-randomized naturalistic ward comparison with partial within-subject crossover (nurses rotated wards every 6 weeks; fixed-effects regression; order not randomized),"Nurses/nurse assistants in an acute psychiatric inpatient unit (St. Olavs Hospital, Trondheim, Norway); shift workers (evening/night shifts).",Structural proxy: shift work (evening/night shifts) with diary-rated sleepiness during shifts.,25,workplace,light,"Blue-depleted light environment (BDLE) ward: from 18:30-07:00, light fixtures + incident light depleted of blue wavelengths (<530 nm); photopic lux similar to standard ward but melanopic lux lower; nurses could not manually change lighting; daytime lighting similar across wards.",Standard hospital light environment (STLE) ward; nurses rotated wards per preset schedule (6-week rotations).,42,sleepiness,Subjective sleepiness (1-5) after each shift (work diary),Evening shifts during 14-day diary window (BDLE vs STLE; within-subject fixed-effects model),worsens,Sleepiness higher in BDLE vs STLE during evening shifts: +17% (p=0.034; Cohen's d=0.49).,no,Work diary + sleep diary + actigraphy for 14 consecutive days toward end of each 6-week ward rotation; participation rate 29.1% of eligible staff.,Primary effect observed is increased evening sleepiness in BDLE; no differences in sleep quantity/quality measures reported.,Intervention + design: PDF p2 (Methods: ward setup; BDLE window 18:30-07:00; melanopic vs photopic lux). Outcomes: PDF p3 (work diary sleepiness 1-5). Results: PDF p4 (fixed-effects model; 17% increase). Abstract: PDF p1.,0ce4a2e73ff6262c
W4285731316,Kjorstad 2022 (BMC Nursing),2022,non-randomized naturalistic ward comparison with partial within-subject crossover (nurses rotated wards every 6 weeks; fixed-effects regression; order not randomized),"Nurses/nurse assistants in an acute psychiatric inpatient unit (St. Olavs Hospital, Trondheim, Norway); shift workers (evening/night shifts).",Structural proxy: shift work (evening/night shifts) with diary-rated sleepiness during shifts.,25,workplace,light,"Blue-depleted light environment (BDLE) ward: from 18:30-07:00, light fixtures + incident light depleted of blue wavelengths (<530 nm); photopic lux similar to standard ward but melanopic lux lower; nurses could not manually change lighting; daytime lighting similar across wards.",Standard hospital light environment (STLE) ward; nurses rotated wards per preset schedule (6-week rotations).,42,other,Caffeinated beverages consumed per shift (count; work diary),Night shifts during 14-day diary window (STLE vs BDLE),unclear,0.2 higher number of caffeinated beverages during night shifts in STLE vs BDLE (p=0.027; Cohen's d=0.37).,no,Work diary + sleep diary + actigraphy for 14 consecutive days toward end of each 6-week ward rotation; participation rate 29.1% of eligible staff.,Behavioral outcome; directionality may reflect compensation rather than arousal per se.,Work diary measures: PDF p3. Results: PDF p4. Abstract: PDF p1.,0ce4a2e73ff6262c
W4285731316,Kjorstad 2022 (BMC Nursing),2022,non-randomized naturalistic ward comparison with partial within-subject crossover (nurses rotated wards every 6 weeks; fixed-effects regression; order not randomized),"Nurses/nurse assistants in an acute psychiatric inpatient unit (St. Olavs Hospital, Trondheim, Norway); shift workers (evening/night shifts).",Structural proxy: shift work (evening/night shifts) with diary-rated sleepiness during shifts.,25,workplace,light,"Blue-depleted light environment (BDLE) ward: from 18:30-07:00, light fixtures + incident light depleted of blue wavelengths (<530 nm); photopic lux similar to standard ward but melanopic lux lower; nurses could not manually change lighting; daytime lighting similar across wards.",Standard hospital light environment (STLE) ward; nurses rotated wards per preset schedule (6-week rotations).,42,sleep_quality,Sleep measures (sleep diary + actigraphy: TST/SE and related sleep variables),Between shifts during 14-day monitoring window (BDLE vs STLE),null,No significant differences on any sleep measures (sleep diary or actigraphy) between BDLE and STLE.,no,Work diary + sleep diary + actigraphy for 14 consecutive days toward end of each 6-week ward rotation; participation rate 29.1% of eligible staff.,Paper reports null sleep effects; detailed light metrics referenced to prior publication.,"Abstract: PDF p1. Results summary: PDF p4 (""no significant differences on any sleep measures"").",0ce4a2e73ff6262c
W2912284734,Chellappa 2019 (Scientific Reports),2019,"within-subject randomized crossover; two 3-day inpatient lab protocols (simulated day shift = circadian alignment vs simulated night shift = circadian misalignment), separated by 3-8 weeks; cognitive testing on Day 2","Healthy chronic shift workers (night work frequency mean 12/night shifts per month); n=9 completed; analysis excludes 2 with unstable DLMO, final n=7 (3 men, 4 women; age 37±7).",Structural proxy: chronic night shift work; experimentally induced low arousal via circadian misalignment and extended wakefulness; KSS sleepiness higher during misalignment.,7,lab,sleep_timing,"Simulated day shift protocol: sleep 23:00-07:00 for days 1-3. Simulated night shift protocol: 12h inversion on day 1 via 8h wake + 4h sleep opportunity (15:00-19:00), then 16h wake; subsequent 8h sleep opportunities 11:00-19:00 through day 3; cognitive battery timing inverted by 12h under misalignment.",Circadian alignment (simulated day shift) vs circadian misalignment (simulated night shift) within-subject.,3,vigilance,Psychomotor Vigilance Task (PVT): 10% slowest reaction times (log-transformed),Day 2; mixed model across time since scheduled wake (7h and 11h); post-hoc at 11h since wake,worsens,"Main effect condition F(1,18)=3.5, p=0.04; condition x time-since-wake interaction F(1,18)=6.6, p=0.02; misalignment slower particularly at 11h since scheduled wake (post-hoc p<0.05).",no,Inpatient protocol with strict environmental control; actigraphy + diaries for >=14 days prior to each lab visit.,Small n; effects strongest after prolonged wakefulness (>10h).,Results: PDF p2 (PVT F-stats + interaction; 11h post-hoc). Protocol: PDF p7 (3-day alignment vs misalignment).,c8982852d40de2f5
W2912284734,Chellappa 2019 (Scientific Reports),2019,"within-subject randomized crossover; two 3-day inpatient lab protocols (simulated day shift = circadian alignment vs simulated night shift = circadian misalignment), separated by 3-8 weeks; cognitive testing on Day 2","Healthy chronic shift workers (night work frequency mean 12/night shifts per month); n=9 completed; analysis excludes 2 with unstable DLMO, final n=7 (3 men, 4 women; age 37±7).",Structural proxy: chronic night shift work; experimentally induced low arousal via circadian misalignment and extended wakefulness; KSS sleepiness higher during misalignment.,7,lab,sleep_timing,"Simulated day shift protocol: sleep 23:00-07:00 for days 1-3. Simulated night shift protocol: 12h inversion on day 1 via 8h wake + 4h sleep opportunity (15:00-19:00), then 16h wake; subsequent 8h sleep opportunities 11:00-19:00 through day 3; cognitive battery timing inverted by 12h under misalignment.",Circadian alignment (simulated day shift) vs circadian misalignment (simulated night shift) within-subject.,3,vigilance,PVT lapses (log-transformed),Day 2; mixed model across time since scheduled wake (7h and 11h),worsens,"Main effect condition F(1,18)=7.3, p=0.02; condition x time-since-wake interaction F(1,18)=15.4, p=0.001; more lapses under misalignment, particularly later in wake episode.",no,Inpatient protocol with strict environmental control; actigraphy + diaries for >=14 days prior to each lab visit.,Supports circadian misalignment increasing state instability.,Results: PDF p2 (PVT lapses F-stats + interaction).,c8982852d40de2f5
W2912284734,Chellappa 2019 (Scientific Reports),2019,"within-subject randomized crossover; two 3-day inpatient lab protocols (simulated day shift = circadian alignment vs simulated night shift = circadian misalignment), separated by 3-8 weeks; cognitive testing on Day 2","Healthy chronic shift workers (night work frequency mean 12/night shifts per month); n=9 completed; analysis excludes 2 with unstable DLMO, final n=7 (3 men, 4 women; age 37±7).",Structural proxy: chronic night shift work; experimentally induced low arousal via circadian misalignment and extended wakefulness; KSS sleepiness higher during misalignment.,7,lab,sleep_timing,"Simulated day shift protocol: sleep 23:00-07:00 for days 1-3. Simulated night shift protocol: 12h inversion on day 1 via 8h wake + 4h sleep opportunity (15:00-19:00), then 16h wake; subsequent 8h sleep opportunities 11:00-19:00 through day 3; cognitive battery timing inverted by 12h under misalignment.",Circadian alignment (simulated day shift) vs circadian misalignment (simulated night shift) within-subject.,3,vigilance,Digit Symbol Substitution Test (DSST): correct responses per minute,"Day 2; mixed model across time since scheduled wake (5h,7h,9h,11h)",worsens,"No main effect condition (F(1,46)=0.1, p=0.33), but condition x time interaction F(1,46)=6.6, p=0.01; DSST improved over time only under alignment (post-hoc at 11h p<0.05).",no,Inpatient protocol with strict environmental control; actigraphy + diaries for >=14 days prior to each lab visit.,Misalignment blunts expected improvement with time awake under alignment.,Results: PDF p3 (DSST interaction stats).,c8982852d40de2f5
W2912284734,Chellappa 2019 (Scientific Reports),2019,"within-subject randomized crossover; two 3-day inpatient lab protocols (simulated day shift = circadian alignment vs simulated night shift = circadian misalignment), separated by 3-8 weeks; cognitive testing on Day 2","Healthy chronic shift workers (night work frequency mean 12/night shifts per month); n=9 completed; analysis excludes 2 with unstable DLMO, final n=7 (3 men, 4 women; age 37±7).",Structural proxy: chronic night shift work; experimentally induced low arousal via circadian misalignment and extended wakefulness; KSS sleepiness higher during misalignment.,7,lab,sleep_timing,"Simulated day shift protocol: sleep 23:00-07:00 for days 1-3. Simulated night shift protocol: 12h inversion on day 1 via 8h wake + 4h sleep opportunity (15:00-19:00), then 16h wake; subsequent 8h sleep opportunities 11:00-19:00 through day 3; cognitive battery timing inverted by 12h under misalignment.",Circadian alignment (simulated day shift) vs circadian misalignment (simulated night shift) within-subject.,3,vigilance,Unstable Tracking Task (TKT): number of losses (log-transformed),"Day 2; mixed model across time since scheduled wake (5h,7h,9h,11h)",worsens,"Main effect condition F(1,40)=4.4, p=0.04; condition x time interaction F(1,46)=10.6, p=0.002; losses increased under misalignment beyond 7h since wake (post-hoc p<0.05).",no,Inpatient protocol with strict environmental control; actigraphy + diaries for >=14 days prior to each lab visit.,Visual-motor operational error proxy worsens under misalignment.,Results: PDF p3 (TKT stats).,c8982852d40de2f5
W2912284734,Chellappa 2019 (Scientific Reports),2019,"within-subject randomized crossover; two 3-day inpatient lab protocols (simulated day shift = circadian alignment vs simulated night shift = circadian misalignment), separated by 3-8 weeks; cognitive testing on Day 2","Healthy chronic shift workers (night work frequency mean 12/night shifts per month); n=9 completed; analysis excludes 2 with unstable DLMO, final n=7 (3 men, 4 women; age 37±7).",Structural proxy: chronic night shift work; experimentally induced low arousal via circadian misalignment and extended wakefulness; KSS sleepiness higher during misalignment.,7,lab,sleep_timing,"Simulated day shift protocol: sleep 23:00-07:00 for days 1-3. Simulated night shift protocol: 12h inversion on day 1 via 8h wake + 4h sleep opportunity (15:00-19:00), then 16h wake; subsequent 8h sleep opportunities 11:00-19:00 through day 3; cognitive battery timing inverted by 12h under misalignment.",Circadian alignment (simulated day shift) vs circadian misalignment (simulated night shift) within-subject.,3,sleepiness,Karolinska Sleepiness Scale (KSS),"Day 2; mixed model across time since scheduled wake (5h,7h,9h,11h)",worsens,"Main effect condition F(1,46)=4.6, p=0.04; condition x time interaction F(1,46)=4.9, p=0.03; sleepiness higher under misalignment beyond 7h since wake.",no,Inpatient protocol with strict environmental control; actigraphy + diaries for >=14 days prior to each lab visit.,Subjective sleepiness tracks performance deficits under misalignment (reported correlations).,Results: PDF p3 (KSS main + interaction).,c8982852d40de2f5
W2912284734,Chellappa 2019 (Scientific Reports),2019,"within-subject randomized crossover; two 3-day inpatient lab protocols (simulated day shift = circadian alignment vs simulated night shift = circadian misalignment), separated by 3-8 weeks; cognitive testing on Day 2","Healthy chronic shift workers (night work frequency mean 12/night shifts per month); n=9 completed; analysis excludes 2 with unstable DLMO, final n=7 (3 men, 4 women; age 37±7).",Structural proxy: chronic night shift work; experimentally induced low arousal via circadian misalignment and extended wakefulness; KSS sleepiness higher during misalignment.,7,lab,sleep_timing,"Simulated day shift protocol: sleep 23:00-07:00 for days 1-3. Simulated night shift protocol: 12h inversion on day 1 via 8h wake + 4h sleep opportunity (15:00-19:00), then 16h wake; subsequent 8h sleep opportunities 11:00-19:00 through day 3; cognitive battery timing inverted by 12h under misalignment.",Circadian alignment (simulated day shift) vs circadian misalignment (simulated night shift) within-subject.,3,sleep_quality,Sleep efficiency (polysomnography) in sleep episode preceding cognitive testing,Across protocols (alignment nocturnal sleep vs misalignment daytime sleep),worsens,"Sleep efficiency lower under misalignment: main effect condition F(1,6)=21.6, p=0.004.",no,Inpatient protocol with strict environmental control; actigraphy + diaries for >=14 days prior to each lab visit.,Lower sleep efficiency during daytime sleep may contribute to reduced alertness under misalignment.,Results: PDF p4 (sleep efficiency main effect). Methods: PDF p7-8 (polysomnography description).,c8982852d40de2f5
W4311622325,Cyr 2022 (PsyArXiv preprint),2022,mixed-design randomized controlled trial with baseline observation period + two intervention periods (three non-consecutive 10-day blocks with similar shift schedules; gaps between blocks); mixed-effects models,"Healthy full-time nurses working rapidly rotating shift schedules; N=57 completed (control n=29, experimental n=28).",Structural proxy: night shift work and fatigue/sleepiness measured twice daily (DFSF; KSS).,57,workplace,light,"Experimental: evening bright light exposure (portable light box nominal 10,000 lux; ~5,500 lux measured with UV filter) for 40 min before night shift + morning light avoidance (dark sunglasses on commute home) + optional nap + sleep scheduling guidance (phase-delay components). Control: chrononutrition guidance (meal timing/content) intended to match expectations without direct circadian targeting.",Experimental vs active control; compared to baseline observation period within each group.,20,other,Work-related errors per shift (self-reported errors + near-errors),Baseline vs intervention periods (10-day blocks); between-group comparison via chi-square,improves,"Fewer errors during experimental intervention: chi-square chi^2(1, N=90)=5.61, p=0.018. Control: 19 baseline errors vs ~18 per intervention period (5% reduction). Experimental: 21 baseline vs ~7 per intervention period (67% reduction).",no,Daily questionnaires completion ~85-87%. Experimental: light box used on 91% suggested days (mean 48.85 min); sunglasses used on 83% commutes home; sleep mask use low (29%).,Errors were self-reported but detailed; reduction partially mediated by pre-shift fatigue in exploratory mediation.,Errors results: PDF p11 (chi-square; counts; mediation summary). Abstract: PDF p2 (67% vs 5%).,182faeb788619fa5
W4311622325,Cyr 2022 (PsyArXiv preprint),2022,mixed-design randomized controlled trial with baseline observation period + two intervention periods (three non-consecutive 10-day blocks with similar shift schedules; gaps between blocks); mixed-effects models,"Healthy full-time nurses working rapidly rotating shift schedules; N=57 completed (control n=29, experimental n=28).",Structural proxy: night shift work and fatigue/sleepiness measured twice daily (DFSF; KSS).,57,workplace,light,"Experimental: evening bright light exposure (portable light box nominal 10,000 lux; ~5,500 lux measured with UV filter) for 40 min before night shift + morning light avoidance (dark sunglasses on commute home) + optional nap + sleep scheduling guidance (phase-delay components). Control: chrononutrition guidance (meal timing/content) intended to match expectations without direct circadian targeting.",Experimental vs active control; compared to baseline observation period within each group.,20,fatigue,Daily Fatigue Short Form (DFSF; 7-35),Across baseline + intervention periods; work days vs days off (mixed-effects; key interaction),improves,"Both groups improved over time (period effect B=-0.50, p<0.001), but experimental showed larger reductions on work days: period x condition x work B=-0.70 (beta=-0.13), 95% CI [-0.24,-0.01], t=-2.08, p=0.019. Work-day comparison: control 15.24 vs experimental 13.89, d=0.25 [0.12,0.38].",no,Daily questionnaires completion ~85-87%. Experimental: light box used on 91% suggested days (mean 48.85 min); sunglasses used on 83% commutes home; sleep mask use low (29%).,Suggests evening light protocol reduces fatigue on work days beyond an active control.,Fatigue narrative + d: PDF p12. Regression Table 2: PDF p12. Descriptives Table 3: PDF p13.,182faeb788619fa5
W4311622325,Cyr 2022 (PsyArXiv preprint),2022,mixed-design randomized controlled trial with baseline observation period + two intervention periods (three non-consecutive 10-day blocks with similar shift schedules; gaps between blocks); mixed-effects models,"Healthy full-time nurses working rapidly rotating shift schedules; N=57 completed (control n=29, experimental n=28).",Structural proxy: night shift work and fatigue/sleepiness measured twice daily (DFSF; KSS).,57,workplace,light,"Experimental: evening bright light exposure (portable light box nominal 10,000 lux; ~5,500 lux measured with UV filter) for 40 min before night shift + morning light avoidance (dark sunglasses on commute home) + optional nap + sleep scheduling guidance (phase-delay components). Control: chrononutrition guidance (meal timing/content) intended to match expectations without direct circadian targeting.",Experimental vs active control; compared to baseline observation period within each group.,20,sleepiness,Karolinska Sleepiness Scale (KSS; 1-9),Across baseline + intervention periods (mixed-effects; period effect),improves,"Sleepiness decreased over time in both groups: period effect B=-0.21 (beta=-0.10), 95% CI [-0.16,-0.04], t=-3.35, p<0.001. No clear differential by condition (period x condition p=0.934).",no,Daily questionnaires completion ~85-87%. Experimental: light box used on 91% suggested days (mean 48.85 min); sunglasses used on 83% commutes home; sleep mask use low (29%).,Active control also reduced sleepiness; primary between-group advantage is errors + work-day fatigue.,Regression Table 2 (Sleepiness/KSS): PDF p12. Descriptives Table 3: PDF p13.,182faeb788619fa5
W4311622325,Cyr 2022 (PsyArXiv preprint),2022,mixed-design randomized controlled trial with baseline observation period + two intervention periods (three non-consecutive 10-day blocks with similar shift schedules; gaps between blocks); mixed-effects models,"Healthy full-time nurses working rapidly rotating shift schedules; N=57 completed (control n=29, experimental n=28).",Structural proxy: night shift work and fatigue/sleepiness measured twice daily (DFSF; KSS).,57,workplace,light,"Experimental: evening bright light exposure (portable light box nominal 10,000 lux; ~5,500 lux measured with UV filter) for 40 min before night shift + morning light avoidance (dark sunglasses on commute home) + optional nap + sleep scheduling guidance (phase-delay components). Control: chrononutrition guidance (meal timing/content) intended to match expectations without direct circadian targeting.",Experimental vs active control; compared to baseline observation period within each group.,20,sleep_quality,Main sleep duration (hours; longest sleep episode) and sleep quality (SQS),Across baseline + intervention periods (mixed-effects; period effect),mixed,Small increase in main sleep duration over time: period effect p=0.049 (Table 2). Sleep quality SQS showed no strong period or interaction effects reported in Table 2 excerpt; work days strongly reduced duration/quality regardless of condition.,no,Daily questionnaires completion ~85-87%. Experimental: light box used on 91% suggested days (mean 48.85 min); sunglasses used on 83% commutes home; sleep mask use low (29%).,Included for context; not primary driver of error reduction per authors.,Regression Table 2 (sleep duration; SQS): PDF p12-13. Descriptives Table 3: PDF p13.,182faeb788619fa5
W4385264619,Bogataj 2023 (Aging Clinical and Experimental Research),2023,parallel-group randomized controlled trial (hemodialysis patients) with pre/post assessment,"Hemodialysis patients; N=44 randomized (EXP n=22, CON n=22).",Clinical population with cognitive deficits; attention/alertness assessed via reaction-time subtest (TAP Alertness).,44,clinical,multi,"Intradialytic combined intervention: cycling exercise + tablet-based cognitive training, 3 sessions/week during dialysis for 12 weeks.",Standard care control group.,84,vigilance,Test of Attentional Performance (TAP) Alertness subtest: reaction time (ms),Pre vs post 12-week intervention; group x time interaction,improves,"Group x time interaction F(1,41)=6.15, p=0.017, eta^2=0.13. Alertness RT (ms): EXP 391±117 -> 348±94 (change +43.3, 95% CI [-8.7, 95.3], p=0.098, ES=+0.37); CON 428±216 -> 455±236 (change -26.7, 95% CI [-52.0, -1.4], p=0.040, ES=-0.48).",no,Sessions missed mainly due to pain/fatigue/clinical issues; cognitive sessions missed mostly due to fatigue or COVID-19 isolation (reported qualitatively).,Intervention primarily preserved alertness vs deterioration under standard care; other attention domains (selective/divided) showed null interactions.,Table 2 (TAP pre/post values): PDF p5. Results interaction F-stats: PDF p? (text near Table 2; extracted around Table 2 in PDF p5). Alertness subtest description: PDF p4.,088b64daf9bf2d00
W2800765696,Swinbourne 2018 (Sports),2018,"pre-post control-trial: 3-week high-intensity training block (control) then 2-week maintenance, then 3-week sleep extension intervention block (sequential; non-randomized)",Professional male rugby union players (n=25; age 25±2.7).,Not selected for low arousal; daytime sleepiness tracked via ESS; preseason training associated with poor sleep.,25,field,sleep_timing,"Sleep extension program during 3-week training block: target 10 hours sleep/night; education on sleep scheduling, strategic napping, and sleep environment control (light/noise/temperature).",Initial 3-week control training block without sleep extension (sequential design).,21,vigilance,Psychomotor Vigilance Test (PVT; 5-min): mean reaction time (ms),Pre vs post sleep extension block (start vs end of 3-week intervention),improves,Mean RT 228.8±24.5 ms (pre) -> 220.0±18.4 (post); reported change -4.3% (±3.1%).,no,Sleep diaries + actigraphy (subset with usable actigraphy nights) and weekly questionnaires; dietary routines verbally checked.,Sequential design; RT measured at baseline control and during intervention pre/post; interpret as suggestive durability evidence over 3 weeks.,Design: PDF p2 (Research Design). PVT method: PDF p4 (Reaction Times). Table 5 (RT values): PDF p6.,60c99d80e54241ca
W2800765696,Swinbourne 2018 (Sports),2018,"pre-post control-trial: 3-week high-intensity training block (control) then 2-week maintenance, then 3-week sleep extension intervention block (sequential; non-randomized)",Professional male rugby union players (n=25; age 25±2.7).,Not selected for low arousal; daytime sleepiness tracked via ESS; preseason training associated with poor sleep.,25,field,sleep_timing,"Sleep extension program during 3-week training block: target 10 hours sleep/night; education on sleep scheduling, strategic napping, and sleep environment control (light/noise/temperature).",Initial 3-week control training block without sleep extension (sequential design).,21,vigilance,PVT errors (count),Pre vs post sleep extension block,improves,Errors 2.6±3.0 (pre) -> 0.8±1.1 (post).,no,Sleep diaries + actigraphy (subset with usable actigraphy nights) and weekly questionnaires; dietary routines verbally checked.,PVT errors decrease aligns with improved vigilance.,Table 5 (RT values): PDF p6.,60c99d80e54241ca
W2800765696,Swinbourne 2018 (Sports),2018,"pre-post control-trial: 3-week high-intensity training block (control) then 2-week maintenance, then 3-week sleep extension intervention block (sequential; non-randomized)",Professional male rugby union players (n=25; age 25±2.7).,Not selected for low arousal; daytime sleepiness tracked via ESS; preseason training associated with poor sleep.,25,field,sleep_timing,"Sleep extension program during 3-week training block: target 10 hours sleep/night; education on sleep scheduling, strategic napping, and sleep environment control (light/noise/temperature).",Initial 3-week control training block without sleep extension (sequential design).,21,vigilance,PVT slowest 10% time,Pre vs post sleep extension block,worsens,Slowest 10% time 3.0±0.5 (pre) -> 3.3±0.5 (post); authors report moderate increase (11.7% ±7.2%).,no,Sleep diaries + actigraphy (subset with usable actigraphy nights) and weekly questionnaires; dietary routines verbally checked.,Counterintuitive worsening in worst-decile responses despite mean improvement; may reflect measurement/unit issues or residual lapses.,Table 5 (RT values): PDF p6; narrative: PDF p6 (Reaction Times summary).,60c99d80e54241ca
W2800765696,Swinbourne 2018 (Sports),2018,"pre-post control-trial: 3-week high-intensity training block (control) then 2-week maintenance, then 3-week sleep extension intervention block (sequential; non-randomized)",Professional male rugby union players (n=25; age 25±2.7).,Not selected for low arousal; daytime sleepiness tracked via ESS; preseason training associated with poor sleep.,25,field,sleep_timing,"Sleep extension program during 3-week training block: target 10 hours sleep/night; education on sleep scheduling, strategic napping, and sleep environment control (light/noise/temperature).",Initial 3-week control training block without sleep extension (sequential design).,21,sleepiness,Epworth Sleepiness Scale (ESS; 0-24),Weekly during control vs sleep extension blocks (Table 2),mixed,"ESS did not show consistent improvement; authors note sleep extension did not improve indices of daytime sleepiness. Table 2 shows week-to-week variability (e.g., week2 control 7.5±2.7 vs intervention 4.8±3.5).",no,Sleep diaries + actigraphy (subset with usable actigraphy nights) and weekly questionnaires; dietary routines verbally checked.,Sleepiness response appears heterogeneous; may limit conclusions about tonic arousal shifts in athletes.,"ESS method: PDF p3. Table 2 (ESS by week): PDF p5. Discussion: PDF p6 (""did not improve indices of daytime sleepiness"").",60c99d80e54241ca
W2794678572,Zanesco 2018 (Journal of Cognitive Enhancement),2018,"stratified random assignment to 3-month residential meditation retreat (training) vs wait-list; longitudinal follow-up at 6 months, 1.5 years, and 7 years; growth-curve models (RIT sustained attention/response inhibition task)",Experienced meditation practitioners (N=60; matched on age/gender/prior meditation); retreat 1 training N=30 and wait-list N=30; wait-list later received identical 3-month retreat.,Not selected for low arousal; sustained attention/response inhibition used as cognitive aging + vigilance outcome.,60,other,other,Full-time 3-month residential meditation training (shamatha; mindfulness of breathing and related practices) with group practice/discussion + ~6h/day solitary practice; follow-up practice hours tracked over 7 years.,Wait-list control during retreat 1 (randomized) + within-person longitudinal follow-up.,90,vigilance,Response inhibition accuracy (perceptual sensitivity A) on 32-min RIT sustained attention/response inhibition task,"Retreat 1: pre/mid/post; plus follow-ups (6 mo, 1.5y, 7y); growth-curve parameters",improves,"Growth model (retreat 1 training participants): linear training effect +0.126 (SE 0.017), p<0.01; quadratic training^2 -0.045 (SE 0.008), p<0.01 (Table 2). Authors report improvements during intensive practice partially maintained several years later, moderated by continued practice.",yes,Residential retreat format; follow-up includes self-reported continued practice hours (median ~1896h across follow-up).,Durability framing: maintenance depends on continued practice; aging-related decrements moderated by continued practice.,Participants + design: PDF p3 (Method; N=60; stratified random assignment; retreat 1 vs wait-list). Follow-up schedule: PDF p4. Growth model Table 2: PDF p7.,e5b5981441cd132b
W2794678572,Zanesco 2018 (Journal of Cognitive Enhancement),2018,"stratified random assignment to 3-month residential meditation retreat (training) vs wait-list; longitudinal follow-up at 6 months, 1.5 years, and 7 years; growth-curve models (RIT sustained attention/response inhibition task)",Experienced meditation practitioners (N=60; matched on age/gender/prior meditation); retreat 1 training N=30 and wait-list N=30; wait-list later received identical 3-month retreat.,Not selected for low arousal; sustained attention/response inhibition used as cognitive aging + vigilance outcome.,60,other,other,Full-time 3-month residential meditation training (shamatha; mindfulness of breathing and related practices) with group practice/discussion + ~6h/day solitary practice; follow-up practice hours tracked over 7 years.,Wait-list control during retreat 1 (randomized) + within-person longitudinal follow-up.,90,vigilance,Reaction time variability (RTCV) during RIT,Retreat training + years since retreat (YSR) follow-up slope,mixed,"RTCV decreased during training: linear training -0.0125 (SE 0.004), p<0.01; RTCV increased across years since retreat: linear YSR +0.056 (SE 0.018), p<0.01 (Table 2).",yes,Residential retreat format; follow-up includes self-reported continued practice hours (median ~1896h across follow-up).,Pattern consistent with training-related improvement plus partial decay without sustained practice.,Growth model Table 2: PDF p7; narrative maintenance: PDF p1 Abstract + Results (near Table 2).,e5b5981441cd132b
W2793708084,Wong 2018 (Frontiers in Human Neuroscience),2018,single-arm pre/post mindfulness-based training (MBT); attendance as covariate in ANCOVA; no control group,"Shift-working nurses; recruited n=46; analyzed n=36 with pre and post sessions (mean age 30.3, SD 8.52; 2 male).",Structural proxy: shift-working nurses; sustained attention assessed via 20-min PVT with time-on-task fatigue; subjective energy depletion measured pre/post PVT.,36,lab,other,8-week MBT (8 weekly 90-min sessions; MBSR-based; formal + informal practices; encouraged >=15 min/day home practice).,Within-subject pre vs post intervention (session S1 vs S2).,56,vigilance,PVT median response speed (RS) (20-min PVT),Pre (S1) vs post (S2) MBT (ANCOVA with attendance covariate),worsens,"Session effect F(1,34)=10.571, p=0.003, eta_p^2=0.237; average RS decreased (S1 median 2.97 (SD 0.29) vs S2 median 2.86 (SD 0.28)). Attendance correlated with RS change r=0.322, p=0.055 (higher attendance = less decline).",no,Attendance varied widely (0-8 sessions); used as covariate; 10/46 did not return for post session.,"Interpretation: sustained attention worsened over 8 weeks overall, but decline mitigated by higher MBT attendance.",Methods + intervention: PDF p3. PVT method + analysis: PDF p4. PVT RS results: PDF p6.,98edb5fba4073744
W2793708084,Wong 2018 (Frontiers in Human Neuroscience),2018,single-arm pre/post mindfulness-based training (MBT); attendance as covariate in ANCOVA; no control group,"Shift-working nurses; recruited n=46; analyzed n=36 with pre and post sessions (mean age 30.3, SD 8.52; 2 male).",Structural proxy: shift-working nurses; sustained attention assessed via 20-min PVT with time-on-task fatigue; subjective energy depletion measured pre/post PVT.,36,lab,other,8-week MBT (8 weekly 90-min sessions; MBSR-based; formal + informal practices; encouraged >=15 min/day home practice).,Within-subject pre vs post intervention (session S1 vs S2).,56,vigilance,PVT lapses (RT>500 ms) (20-min PVT),Pre vs post MBT (ANCOVA with attendance covariate),worsens,"Session effect F(1,33)=6.177, p=0.018, eta_p^2=0.158; lapses increased on average (S1 mean 7.60 (SD 3.45) vs S2 mean 8.94 (SD 7.16)). Attendance correlated with lapse change r=-0.348, p=0.04 (higher attendance = fewer lapses).",no,Attendance varied widely (0-8 sessions); used as covariate; 10/46 did not return for post session.,Shows state instability over time; MBT attendance appears protective.,PVT lapse results + attendance correlations: PDF p6.,98edb5fba4073744
W2793708084,Wong 2018 (Frontiers in Human Neuroscience),2018,single-arm pre/post mindfulness-based training (MBT); attendance as covariate in ANCOVA; no control group,"Shift-working nurses; recruited n=46; analyzed n=36 with pre and post sessions (mean age 30.3, SD 8.52; 2 male).",Structural proxy: shift-working nurses; sustained attention assessed via 20-min PVT with time-on-task fatigue; subjective energy depletion measured pre/post PVT.,36,lab,other,8-week MBT (8 weekly 90-min sessions; MBSR-based; formal + informal practices; encouraged >=15 min/day home practice).,Within-subject pre vs post intervention (session S1 vs S2).,56,fatigue,Subjective energy (Likert) pre vs post PVT,Session x time (pre/post PVT) across S1 vs S2,mixed,"Time effect F(1,33)=5.679, p=0.023; session x time interaction F(1,33)=5.034, p=0.032, eta_p^2=0.132; attendance correlated with energy change r=0.372, p=0.028 (higher attendance = smaller energy decrease after PVT).",no,Attendance varied widely (0-8 sessions); used as covariate; 10/46 did not return for post session.,Energy depletion from sustained attention task reduced among higher-attendance participants.,Subjective energy results: PDF p7.,98edb5fba4073744
W2793708084,Wong 2018 (Frontiers in Human Neuroscience),2018,single-arm pre/post mindfulness-based training (MBT); attendance as covariate in ANCOVA; no control group,"Shift-working nurses; recruited n=46; analyzed n=36 with pre and post sessions (mean age 30.3, SD 8.52; 2 male).",Structural proxy: shift-working nurses; sustained attention assessed via 20-min PVT with time-on-task fatigue; subjective energy depletion measured pre/post PVT.,36,lab,other,8-week MBT (8 weekly 90-min sessions; MBSR-based; formal + informal practices; encouraged >=15 min/day home practice).,Within-subject pre vs post intervention (session S1 vs S2).,56,physiology,EEG individual alpha power during 4-min guided meditation,Pre vs post MBT,mixed,"Alpha power increased across regions post MBT (e.g., parietal F(1,34)=18.620, q=0.00002; eta^2 ~0.29-0.35). Alpha power change correlated with attendance (r ~0.436-0.524; q<=0.008) (Table 2).",no,Attendance varied widely (0-8 sessions); used as covariate; 10/46 did not return for post session.,Physiology context; interpretation depends on whether alpha increase reflects relaxed wakefulness vs reduced arousal.,Table 2 (alpha power + attendance correlations): PDF p5.,98edb5fba4073744
W2793708084,Wong 2018 (Frontiers in Human Neuroscience),2018,single-arm pre/post mindfulness-based training (MBT); attendance as covariate in ANCOVA; no control group,"Shift-working nurses; recruited n=46; analyzed n=36 with pre and post sessions (mean age 30.3, SD 8.52; 2 male).",Structural proxy: shift-working nurses; sustained attention assessed via 20-min PVT with time-on-task fatigue; subjective energy depletion measured pre/post PVT.,36,lab,other,8-week MBT (8 weekly 90-min sessions; MBSR-based; formal + informal practices; encouraged >=15 min/day home practice).,Within-subject pre vs post intervention (session S1 vs S2).,56,physiology,P3 ERP amplitude (Pz; 300-400 ms) during PVT time-on-task,First vs last 4 min of PVT; pre vs post MBT,improves,"Session effect F(1,33)=6.829, p=0.013; time effect F(1,33)=9.049, p=0.005; session x time interaction F(1,33)=7.667, p=0.009 driven by smaller decreases over time in post-intervention session.",no,Attendance varied widely (0-8 sessions); used as covariate; 10/46 did not return for post session.,Neural marker consistent with improved sustained attention stability post MBT (time-on-task attenuation).,ERP results: PDF p7.,98edb5fba4073744
W2570795284,Aziz 2017 (Sports),2017,"within-subject crossover with 3 trials: control before Ramadan (CON1), Ramadan-fasted (RAM), and control after Ramadan (CON2); standardized 24h meals; actigraphy sleep measurement",Trained Muslim footballers (N=14).,Contextual low arousal via fasting + sleepiness measures (KSS) and VAS alertness/tiredness/concentration.,14,field,other,Ramadan fasting month; trials conducted before/during/after; sleep objectively measured with actigraphy 24h prior; KSS and VAS readiness/tiredness/alertness/concentration collected pre-exercise.,Non-fasted control trials before and after Ramadan month.,28,sleepiness,Karolinska Sleepiness Scale (KSS),Day of exercise trial (pre-exercise) across CON1 vs RAM vs CON2,worsens,KSS (mean±SD): CON1 3.3±0.9; RAM 4.2±1.6; CON2 3.8±1.7 (Table 5).,no,Standardized pre-packed 24h meals and monitoring of sleep/training load; actigraphy 24h prior to each trial.,KSS higher during Ramadan trial vs pre-Ramadan control; p-value not clearly reported for KSS in extracted text.,Sleep + KSS methods: PDF p7. Table 5 (sleep duration + KSS): PDF p13.,46516a15d286e8b5
W2570795284,Aziz 2017 (Sports),2017,"within-subject crossover with 3 trials: control before Ramadan (CON1), Ramadan-fasted (RAM), and control after Ramadan (CON2); standardized 24h meals; actigraphy sleep measurement",Trained Muslim footballers (N=14).,Contextual low arousal via fasting + sleepiness measures (KSS) and VAS alertness/tiredness/concentration.,14,field,other,Ramadan fasting month; trials conducted before/during/after; sleep objectively measured with actigraphy 24h prior; KSS and VAS readiness/tiredness/alertness/concentration collected pre-exercise.,Non-fasted control trials before and after Ramadan month.,28,sleep_quality,Sleep duration night prior to trial (actigraphy; hours),24h prior to each trial,null,Sleep duration (h): CON1 7.5±1.0; RAM 7.9±2.8; CON2 7.7±1.9; authors report no significant differences between trials for sleep duration.,no,Standardized pre-packed 24h meals and monitoring of sleep/training load; actigraphy 24h prior to each trial.,Sleep quantity controlled/monitored; arousal differences likely not driven by gross sleep duration changes.,Sleep methods: PDF p7. Table 5: PDF p13. Results text: PDF p12-13 (sleep duration).,46516a15d286e8b5
W2570795284,Aziz 2017 (Sports),2017,"within-subject crossover with 3 trials: control before Ramadan (CON1), Ramadan-fasted (RAM), and control after Ramadan (CON2); standardized 24h meals; actigraphy sleep measurement",Trained Muslim footballers (N=14).,Contextual low arousal via fasting + sleepiness measures (KSS) and VAS alertness/tiredness/concentration.,14,field,other,Ramadan fasting month; trials conducted before/during/after; sleep objectively measured with actigraphy 24h prior; KSS and VAS readiness/tiredness/alertness/concentration collected pre-exercise.,Non-fasted control trials before and after Ramadan month.,28,fatigue,"Perceived tiredness and alertness (VAS, mm) pre-exercise",Pre-exercise questionnaire across trials,worsens,Tiredness (mm): CON1 20.4±14.5 vs RAM 44.2±25.1 (post-hoc CON1 vs RAM p<0.017) vs CON2 35.1±24.2. Alertness (mm): CON1 79.6±17.7 vs RAM 70.6±23.1 vs CON2 70.4±20.8. Concentration (mm): CON1 83.6±13.2 vs RAM 76.5±17.2 vs CON2 76.4±15.3 (Table 6).,no,Standardized pre-packed 24h meals and monitoring of sleep/training load; actigraphy 24h prior to each trial.,Subjective arousal/effort measures show increased tiredness in Ramadan trial; objective cognitive measures not included.,Table 6 (VAS readiness/tiredness/alertness/concentration): PDF p13.,46516a15d286e8b5
W2000225665,Gutmann 2015 (Neural Plasticity),2015,within-subject: steady-state vs exhaustive one-legged cycling on separate days; repeated before (T1) and after (T2) 4-week cycling training; EEG measured pre/post/post10,Healthy young adult male volunteers (n=10; age 22.7±2.0).,Physiology proxy: individual alpha peak frequency (iAPF) as marker of state arousal and attention.,10,lab,exercise,"Acute bouts: steady-state exercise (30 min) vs exhaustive ramp exercise; repeated pre and post 4-week cycling training (12 sessions; intensity progressed). Resting-state EEG recorded 2 min pre, immediately post, and 10 min post.",Exhaustive vs steady-state; within-subject pre vs post training.,28,physiology,"Individual alpha peak frequency (iAPF, Hz)",Acute response: pre vs post vs post+10min (exhaustive vs steady-state),improves,"ANOVA time main effect F(2,16)=7.232, p=0.006; protocol x time interaction F(2,16)=3.995, p=0.039. Post-hoc for exhaustive exercise: iAPF increased pre->post (p=0.012) and pre->post10 (p=0.003). Table 2: EE T1 pre 10.23 -> post 10.55 -> post10 10.57.",no,Lab-based protocols; training intensity increased weekly; intersession interval >=36h.,Authors interpret iAPF increase after intense exercise as higher arousal/preparedness for external input.,Study summary + conclusion: PDF p1. Participants + methods: PDF p2. Table 2 + ANOVA/post-hoc: PDF p4.,fe4108f5572c586b
W2000225665,Gutmann 2015 (Neural Plasticity),2015,within-subject: steady-state vs exhaustive one-legged cycling on separate days; repeated before (T1) and after (T2) 4-week cycling training; EEG measured pre/post/post10,Healthy young adult male volunteers (n=10; age 22.7±2.0).,Physiology proxy: individual alpha peak frequency (iAPF) as marker of state arousal and attention.,10,lab,exercise,"Acute bouts: steady-state exercise (30 min) vs exhaustive ramp exercise; repeated pre and post 4-week cycling training (12 sessions; intensity progressed). Resting-state EEG recorded 2 min pre, immediately post, and 10 min post.",Exhaustive vs steady-state; within-subject pre vs post training.,28,physiology,iAPF baseline and training (block) effects,Pre (T1) vs post (T2) 4-week training; baseline pre-exercise values,null,"No significant effects involving training block (T1 vs T2) on iAPF; steady-state exercise showed no iAPF change; 4-week training did not change baseline iAPF (""no significant effects for factor block"").",no,Lab-based protocols; training intensity increased weekly; intersession interval >=36h.,Short-term steady-state training improved fitness but did not shift iAPF baseline in this sample.,Results + discussion: PDF p4-5 (no block effect; iAPF unchanged after SSE; training not sufficient).,fe4108f5572c586b
W3198610695,Ochab 2021 (PLoS ONE),2021,"naturalistic longitudinal within-subject: 21 consecutive days (4d baseline, 10d chronic partial sleep restriction, 7d recovery); daily EEG + Stroop task","Healthy adults recruited by PSQI/ESS; behavioral+EEG sample n=13 (mean age 21.5±1.3; 12 women, 1 man).",Experimentally induced low arousal via 10-day 30% sleep restriction relative to individual sleep need; cognitive efficiency measured daily (Stroop RT/accuracy).,13,field,sleep_timing,Baseline (4d) unrestricted sleep; sleep restriction (10d) prescribed 30% reduction vs individual sleep need (no naps; no caffeine before EEG); recovery (7d) unrestricted sleep.,Within-subject baseline vs sleep restriction vs recovery.,10,vigilance,Stroop task reaction times (RT),Across baseline vs sleep restriction vs recovery (time-on-task analysis),mixed,Authors report RTs deteriorate during sleep restriction vs baseline and return to baseline during recovery (Table 1 summary: BASE->SR yes (increase); SR->RCV yes (decrease); full return).,yes,Compliance monitored; days excluded for noncompliance (32/273 EEG-days excluded).,"Key durability finding: 7 days recovery sufficient for mean RT return, but other measures did not fully recover.",Protocol + participants: PDF p4. Fig 3 + caption: PDF p7. Table 1 summary: PDF p17.,e4905eac94ecd749
W3198610695,Ochab 2021 (PLoS ONE),2021,"naturalistic longitudinal within-subject: 21 consecutive days (4d baseline, 10d chronic partial sleep restriction, 7d recovery); daily EEG + Stroop task","Healthy adults recruited by PSQI/ESS; behavioral+EEG sample n=13 (mean age 21.5±1.3; 12 women, 1 man).",Experimentally induced low arousal via 10-day 30% sleep restriction relative to individual sleep need; cognitive efficiency measured daily (Stroop RT/accuracy).,13,field,sleep_timing,Baseline (4d) unrestricted sleep; sleep restriction (10d) prescribed 30% reduction vs individual sleep need (no naps; no caffeine before EEG); recovery (7d) unrestricted sleep.,Within-subject baseline vs sleep restriction vs recovery.,10,vigilance,Stroop task accuracy (% correct),Across baseline vs sleep restriction vs recovery,worsens,Accuracy decreases during sleep restriction and only partially returns during recovery (Table 1 summary: BASE->SR yes (decrease); SR->RCV partial (increase)).,yes,Compliance monitored; days excluded for noncompliance (32/273 EEG-days excluded).,Suggests incomplete cognitive recovery after 7d despite RT normalization.,Table 1 summary: PDF p17; behavioral measures description: PDF p9.,e4905eac94ecd749
W3198610695,Ochab 2021 (PLoS ONE),2021,"naturalistic longitudinal within-subject: 21 consecutive days (4d baseline, 10d chronic partial sleep restriction, 7d recovery); daily EEG + Stroop task","Healthy adults recruited by PSQI/ESS; behavioral+EEG sample n=13 (mean age 21.5±1.3; 12 women, 1 man).",Experimentally induced low arousal via 10-day 30% sleep restriction relative to individual sleep need; cognitive efficiency measured daily (Stroop RT/accuracy).,13,field,sleep_timing,Baseline (4d) unrestricted sleep; sleep restriction (10d) prescribed 30% reduction vs individual sleep need (no naps; no caffeine before EEG); recovery (7d) unrestricted sleep.,Within-subject baseline vs sleep restriction vs recovery.,10,physiology,EEG ERPs and resting-state power spectra (delta/theta/alpha/beta),Baseline vs sleep restriction vs recovery,worsens,EEG measures show deterioration under sleep restriction with incomplete recovery: Table 1 indicates no return for ERP amplitudes and some band power spectra within 7d recovery.,yes,Compliance monitored; days excluded for noncompliance (32/273 EEG-days excluded).,Provides physiological corroboration that recovery is incomplete even when mean RT recovers.,Table 1 summary: PDF p17; EEG power figures: PDF p16-17 (Figs 6-8).,e4905eac94ecd749
W319466055,Rupp 2008 (Walter Reed / DTIC),2008,parallel-group randomized sleep-extension vs habitual sleep; subsequent in-lab 7-night sleep restriction + 5-night recovery; discontinuous growth modeling; hourly testing,Healthy civilian and active duty military adults (18-39 years).,Experimentally induced low arousal via 7 consecutive nights of sleep restriction (3h time-in-bed).,"24 (12 extended, 12 habitual)",lab (in-laboratory sleep restriction/recovery protocol),sleep_timing,"Extended group: 10h time-in-bed (TIB) for 7 days prior to restriction; Habitual group: maintain habitual sleep (mean ~7.1h) for 7 days. Then 1 baseline night (10h or habitual), 7 nights sleep restriction (3h TIB), and 5 nights recovery (8h TIB). PVT/MWT/SSS administered hourly.",Habitual sleep group (parallel; both groups underwent identical restriction and recovery schedules).,7 (pre-restriction sleep extension period),vigilance,Psychomotor Vigilance Task (PVT) lapses,Across 7-day restriction + 5-day recovery (growth model; group x phase-slope interactions),improves,"Habitual group deteriorated faster during restriction vs extended (RESTRICT x Group coef=0.40, SE=0.17, t=2.35, p=0.01, one-tailed). During recovery, extended recovered rapidly and stabilized while habitual improved gradually (RECOV x Group coef=-0.75, SE=0.39, t=-1.94, p=0.03, one-tailed).",no,In-lab protocol; some missing sessions due to technical issues (handled via missing-robust models).,Interpretation: banking sleep (10h TIB x7d) reduced subsequent vigilance impairment during sleep restriction and accelerated recovery.,Design/assignment: PDF p1 (Abstract) + PDF p3 (Participants). Results: PDF p6-7 (PVT narrative) + PDF p7 (Table 4; Fig 1).,cbe216fc9ae80c3a
W319466055,Rupp 2008 (Walter Reed / DTIC),2008,parallel-group randomized sleep-extension vs habitual sleep; subsequent in-lab 7-night sleep restriction + 5-night recovery; discontinuous growth modeling; hourly testing,Same as above.,7 nights of 3h TIB sleep restriction.,24,lab,sleep_timing,As above.,Habitual sleep group (parallel).,7,sleepiness,Maintenance of Wakefulness Test (MWT) sleep latency,Across restriction + recovery (growth model; restriction slope interaction),improves,"During restriction, habitual group showed shorter sleep latency vs extended (RESTRICT x Group coef=0.68, SE=0.20, t=3.32, p<0.001, one-tailed; Table 5). No clear group differences at transition or recovery slopes (TRANS x Group, RECOV x Group n.s.).",no,In-lab protocol.,Objective alertness during restriction favored the prior sleep-extension group.,Methods: PDF p3 (Participants) + PDF p5 (modeling approach). Results: PDF p7 (MWT narrative) + PDF p8 (Table 5; Fig 2).,cbe216fc9ae80c3a
W4394879532,Wang 2024 (Buildings),2024,within-subject repeated-measures confinement study (8 days) under static lighting; no external control group,20 young male university students (mean age 22.6 +/- 1.88 years) confined to an underground lab with fixed work/sleep schedule.,None explicit; arousal/alertness tracked longitudinally under confined static lighting exposure.,20,lab (confined underground simulation),light,"Static lighting condition: 6000K, ~300 lx desk horizontal illuminance (eye vertical ~121 lx; melanopic EDI ~109 lx) used 08:00-24:00 during 8-day confinement. Dim-light condition (<30 lx) used 19:00-24:00 on nights 1 and 8 for DLMO assessment. Fixed schedule: wake 08:00, work 09:00-12:00 and 19:00-24:00, sleep 24:00-08:00.",Within-subject day-by-day change (early vs late days); no separate control lighting group.,8,vigilance,PVT reaction time (5-min at 10:00),Daily across confinement (reported comparisons day 3/4 vs day 8),worsens,Reaction time decreased on day 3 (practice effect; p=0.050) then increased day-by-day; day 8 reaction time significantly longer than day 3 (p=0.026) and day 4 (p=0.016). Error counts increased trend but not significant.,no,Confined protocol with controlled schedule; participants prohibited from alcohol/coffee; wore sleep bracelet pre-study and during study.,Interpretation: static high-CCT lighting in confinement produced cumulative morning vigilance decrement after initial practice effect.,Protocol: PDF p3-6 (Participants + Light treatment + Experimental protocol). PVT results: PDF p12-13 (Section 3.5; Figure 10).,233f5db47bdf264e
W4394879532,Wang 2024 (Buildings),2024,within-subject repeated-measures confinement study,Same as above.,None explicit; subjective sleepiness tracked hourly.,20,lab,light,As above.,Within-subject across days.,8,sleepiness,Karolinska Sleepiness Scale (KSS) (hourly; focus on wake-up 08:00),Across 8-day confinement,worsens,"KSS at wake-up (08:00) increased day-by-day (Figure 4; between-day differences indicated with * p<0.05, ** p<0.01). KSS at 24:00 before sleep decreased day-by-day (mixed direction depending on time-of-day).",no,Hourly KSS collection 08:00-12:00 and 19:00-24:00 each day.,"Morning subjective sleepiness increased with confined time under static lighting, consistent with a delayed circadian phase discussion.",Measures: PDF p7 (KSS schedule). Results: PDF p8-9 (Section 3.1; Figure 4) + PDF p14 (Discussion summary).,233f5db47bdf264e
W2943827695,Mantua 2019 (Sleep Science),2019,within-subject pre/post sleep extension protocol (2 in-lab baseline nights then 7 nights extended TIB); paired t-tests,"Healthy, normally-sleeping young adults (mean age ~24.4 years; 11/27 female).",None (normal sleepers; no explicit low-arousal selection).,27,home + lab,sleep_timing,"14-day at-home actigraphy baseline, then 2 in-lab baseline nights with 8h TIB, then 7 nights sleep extension with 10h TIB (21:00-07:00).",Within-subject baseline (8h TIB) vs sleep extension (10h TIB).,7,sleep_quality,Total sleep time (TST) (in-lab sleep duration),Baseline nights vs extension nights (means over phases),improves,In-lab baseline sleep duration 465.92 +/- 35.59 min vs sleep extension 561.67 +/- 33.87 min; p<0.001.,no,In-lab TIB controlled; actigraphy worn throughout.,Sleep extension achieved ~1.6h additional sleep/night in lab.,Abstract: PDF p1. Results: PDF p4 (Sleep parameters paragraph).,a77e361f29641a2c
W2943827695,Mantua 2019 (Sleep Science),2019,within-subject pre/post sleep extension protocol,Same as above.,None.,27,lab,sleep_timing,As above.,Within-subject baseline vs extension.,7,fatigue,ANAM mood construct: Fatigue (0-6 Likert; averaged),Last day of baseline phase vs last day of extension phase,improves,"Baseline 1.61 +/- 1.28 vs extension 1.28 +/- 1.07; t(26)=2.36, p=0.03.",no,In-lab phases; mood items from ANAM.,Fatigue decreased without a statistically significant change in subjective sleepiness.,Results: PDF p4 (Table 2; Impact of sleep on mood).,a77e361f29641a2c
W2943827695,Mantua 2019 (Sleep Science),2019,within-subject pre/post sleep extension protocol,Same as above.,None.,27,lab,sleep_timing,As above.,Within-subject baseline vs extension.,7,sleepiness,Karolinska Sleepiness Scale (KSS) (average of 11:00/15:00/19:00 ratings on last day),Baseline vs extension,null,"Baseline 3.86 +/- 1.28 vs extension 3.48 +/- 1.72; t(25)=1.38, p=0.18.",no,KSS administered at 3 daily timepoints on last day of each phase.,No significant subjective sleepiness improvement in already-healthy sleepers.,Results: PDF p4 (Sleepiness paragraph + Table 2).,a77e361f29641a2c
W4237499249,Sutarto 2010 (JIEM),2010,pilot + small RCT replication described within article: HRV resonant-frequency biofeedback (paced breathing) with pre/post cognitive testing; control group monitored without instruction,"Real operators replication: female manufacturing operators (n=20 enrolled; final n=16; 9 training, 7 control).",Occupational/operator fatigue/stress/boredom context (not explicitly selected for low arousal).,"16 (final sample; 9 training, 7 control)",workplace/lab (operator training sessions + cognitive testing),biofeedback,HRV resonant frequency training (paced breathing ~6 breaths/min; diaphragmatic + pursed-lips exhalation). Real operators: 5 HRV biofeedback sessions (30-50 min each; described as weekly) with mental arithmetic stressor added in sessions 4-5. Post assessment 1 week after final session.,Randomized control group attended 5 sessions with physiologic monitoring but no special instruction; pre vs post assessments for both groups.,~21-35 (5 sessions described as weekly; exact calendar duration not fully specified),vigilance,D2 attention test: concentration performance,Pre vs post (post measured 1 week after final training),improves,Training group improved: 103.8 (34.68) -> 150.4 (36.70); p=0.003; effect size r^2=0.63. Authors report control showed no improvements.,no,"Attrition: 1 excluded (finger pulse registration), 3 control dropouts; final n=16 completed pre/post.",Operationally relevant sustained-attention improvement after repeated HRV biofeedback sessions; includes short follow-up (1 week).,Methods (replication): PDF p13 (randomization + sessions + post timing). Results: PDF p14-16 (Section 5.2; Table 3).,7edb551262989a1f
W4237499249,Sutarto 2010 (JIEM),2010,pilot + small RCT replication described within article,Real operators replication (training group pre/post values reported).,Operator context.,16,workplace/lab,biofeedback,As above.,Control group monitored without instruction.,~21-35,vigilance,Sternberg short-term memory test: response time (ms),Pre vs post (post measured 1 week after final training),improves,Training group response time decreased: 1853.47 (503.64) ms -> 1397.09 (164.70) ms; p=0.007; effect size r^2=0.56.,no,As above.,RT improvements align with vigilance/processing speed enhancement after repeated sessions.,Methods: PDF p13. Results: PDF p14-16 (Table 3).,7edb551262989a1f
W4237499249,Sutarto 2010 (JIEM),2010,pilot + small RCT replication described within article,Real operators replication: HRV training progress across 5 sessions.,Operator context.,16,workplace/lab,biofeedback,As above.,"Control group monitored without instruction (LF shift also increased in control per narrative, but training emphasized technique).",~21-35,physiology,HRV spectral LF power shift (% total power shifted to LF range) across sessions,Across sessions 1-5 (within-session progression),improves,"Real operators: Friedman chi^2=14.578, p<0.01; pairwise increases significant for Session2->Session3 (Z=-2.547, p=0.004) and Session4->Session5 (Z=-2.431, p=0.006) under Bonferroni alpha=0.0125 (Table 2).",no,5 training/monitoring sessions attended by completers; details not fully reported.,Physiologic learning signal consistent with improved autonomic regulation (cardiac coherence) alongside cognitive gains.,Protocol description: PDF p11-13 (RFT steps + replication design). Results: PDF p14-15 (Tables 1-2) + PDF p16 (interpretation).,7edb551262989a1f
W2256196379,Famodu 2014 (WVU MS thesis),2014,single-arm pre/post intervention study (1-week baseline actigraphy + 1-week sleep extension; matched paired t-tests; Bonferroni adjustment noted),Collegiate female track and field athletes (n=21 analyzed; mean age 20.2 +/- 1.8 years).,None explicit (athletes; not selected for low baseline arousal).,21,field + lab assessments (Human Performance Lab),sleep_timing,"Participants maintained normal sleep for 1 week (baseline), then instructed to extend sleep by +1 hour/night for 1 week (earlier bedtime and/or later wake; sleep hygiene guidance; individualized sleep target texted). Sleep monitored via actigraphy and sleep logs.",Within-subject baseline week vs sleep extension week.,7,sleep_quality,Total sleep time (actigraphy; minutes/night),Baseline week vs extension week,improves,Total sleep time increased: 429.3 +/- 38.4 min -> 451.3 +/- 44.8 min; p=0.03; Cohen d=0.53 (reported).,no,"Adherence limited: despite +60 min target, achieved +22 min average sleep increase.",Demonstrates feasibility gap between prescribed and achieved sleep extension in athletes.,Abstract: PDF p3. Methods: PDF p33-37 (Study design + actigraphy). Results: PDF p44-48 (Total sleep time; Table 8).,3edfd294cac53f91
W2256196379,Famodu 2014 (WVU MS thesis),2014,single-arm pre/post,Same as above.,None.,21,lab assessment,sleep_timing,As above.,Within-subject baseline vs extension.,7,vigilance,PVT mean reaction time (ms),Baseline vs post sleep extension (assessment time not specified),null,Mean reaction time unchanged: 302.7 +/- 20.2 ms -> 302.8 +/- 23.5 ms; p=0.98 (Table 10).,no,As above.,"Despite modest sleep increase, no detectable PVT RT change in this athletic sample.",Results: PDF p45-48 (Mental performance; Table 10).,3edfd294cac53f91
W2256196379,Famodu 2014 (WVU MS thesis),2014,single-arm pre/post,Same as above.,None.,21,lab assessment,sleep_timing,As above.,Within-subject baseline vs extension.,7,other,POMS Total Mood Disturbance (TMD) score,Baseline vs post sleep extension,improves,TMD decreased: 20.2 +/- 24.5 -> 12.2 +/- 25.7; p=0.01; Cohen d=0.32 (Table 10).,no,As above.,Mood disturbance improved even though PVT RT did not; subscales (anger/tension/depression) trended but not significant after correction.,Results: PDF p45-48 (Mental performance; Tables 10-11).,3edfd294cac53f91
W2977514556,Holzinger 2019 (Arh Hig Rada Toksikol),2019,single-group pre/post (baseline vs 6-month follow-up) evaluation of a 2-day sleep coaching seminar; baseline comparison vs non-completers for bias check,Austrian railway shift workers (completers N=30; mostly male). Non-completers N=154 used for baseline bias check.,"Structural proxy: shift work. Outcomes focus on non-restorative sleep, daytime sleepiness and fatigue (ESS, PSQI).",30,workplace/field (seminar + self-report questionnaires),other,"Two-day sleep coaching seminar (Holzinger & Klösch; Gestalt-therapy-based holistic programme incl. coping strategies, dream work, relaxation techniques) intended to be applied as daily routine.",Within-subject baseline vs 6-month follow-up (same survey before vs 6 months after seminar).,2,sleep_quality,PSQI total score,Baseline vs 6 months after seminar,improves,"7.07±2.79 -> 5.30±2.83 (p<0.01), Cohen d=0.64 (Table 3).",no,Follow-up completion: 30 completers vs 154 non-completers (baseline bias check performed; groups differed on burnout and sleep duration at baseline).,PSQI threshold for poor sleep quality (>5) still exceeded at follow-up per narrative.,Outcome table + stats: PDF p5 (Table 3). Design: PDF p1 (Abstract) + PDF p3 (Methods).,4938027564a0b87b
W2977514556,Holzinger 2019 (Arh Hig Rada Toksikol),2019,single-group pre/post,Same as above.,Shift work; daytime sleepiness assessed via ESS.,30,workplace/field,other,As above.,Baseline vs 6-month follow-up.,2,sleepiness,Epworth Sleepiness Scale (ESS) total score,Baseline vs 6 months after seminar,improves,"8.73±3.75 -> 6.87±3.69 (p<0.01), Cohen d=0.50 (Table 3).",no,As above.,Subjective daytime sleepiness decreased at 6-month follow-up.,PDF p5 (Table 3).,4938027564a0b87b
W2977514556,Holzinger 2019 (Arh Hig Rada Toksikol),2019,single-group pre/post,Same as above.,PSQI component includes daytime dysfunction/diurnal fatigue.,30,workplace/field,other,As above.,Baseline vs 6-month follow-up.,2,fatigue,PSQI diurnal fatigue component,Baseline vs 6 months after seminar,improves,"1.30±0.70 -> 0.90±0.71 (p<0.01), Cohen d=0.57 (Table 3).",no,As above.,Interpreted by authors as improved daytime alertness/safety for train-driver population.,PDF p5 (Table 3) + PDF p5 (Discussion narrative).,4938027564a0b87b
W2977514556,Holzinger 2019 (Arh Hig Rada Toksikol),2019,single-group pre/post,Same as above.,PSQI sleep latency component.,30,workplace/field,other,As above.,Baseline vs 6-month follow-up.,2,sleep_quality,PSQI sleep latency component,Baseline vs 6 months after seminar,improves,"1.67±0.96 -> 1.20±0.81 (p<0.01), Cohen d=0.52 (Table 3).",no,As above.,Shorter sleep latency interpreted as less unnecessary time in bed.,PDF p5 (Table 3) + PDF p5 (Discussion narrative).,4938027564a0b87b
W3132047372,Martin 2021 (Chronobiology International) [abstract-only extraction],2021,"two cross-over field studies; three conditions (blue-light + BBG; red-light + BBG; no-intervention control), each composed of four consecutive night shifts",Police patrol officers on a rotating shift schedule; summer study n=15; winter/early-spring study n=25 (total n=40).,Structural proxy: night shift work with sleepiness/alertness assessed repeatedly during shifts.,40,workplace/field (in-car light intervention during night shifts),light,Condition 1: in-car dim blue light during night shift + blue-blocking glasses in morning after 05:00. Condition 2: in-car red light + BBG after 05:00. Condition 3: control (no intervention).,Within-subject crossover across the three conditions (each 4 consecutive night shifts).,4,vigilance,PVT (10-min) at beginning and end of each night shift,Across four consecutive night shifts per condition,null,Abstract reports no differences in alertness between conditions in summer or winter study (no effect sizes/p-values provided in abstract).,no,Not reported in OpenAlex abstract.,"Full-text PDF was not accessible without publisher access (T&F landing page shows ""Get Access""). Extracted from OpenAlex abstract only.",OpenAlex work abstract (api.openalex.org/works/W3132047372; accessed 2026-02-14).,1c43e085c8ea5730
W3132047372,Martin 2021 (Chronobiology International) [abstract-only extraction],2021,two cross-over field studies; three conditions x 4 consecutive night shifts,Same as above.,KSS completed every 2 h during each night shift (per abstract).,40,workplace/field,light,As above.,Within-subject crossover.,4,sleepiness,Karolinska Sleepiness Scale (KSS) every 2 h during shifts,Across four consecutive night shifts per condition,null,Abstract reports no differences in sleepiness between conditions in either study (no effect sizes/p-values provided in abstract).,no,Not reported in abstract.,"Abstract-only extraction; interpret as context, not core evidence.",OpenAlex work abstract (api.openalex.org/works/W3132047372; accessed 2026-02-14).,1c43e085c8ea5730
W3132047372,Martin 2021 (Chronobiology International) [abstract-only extraction],2021,two cross-over field studies,Same as above.,Circadian phase assessed via salivary melatonin (DLMO) collected hourly night before and after each condition (per abstract).,40,workplace/field,light,As above.,Within-subject crossover (blue vs red vs control).,4,physiology,Circadian phase shift (DLMO delay) after each 4-night condition,Pre vs post each 4-night condition,mixed,Summer: greater ~3 h phase delay in control vs ~2 h in blue/red conditions (per abstract). Winter/early spring: ~2 h phase delay in all conditions (per abstract).,no,Not reported in abstract.,Abstract-only extraction; direction relative to desired adaptation is context-dependent. Supplemental PDF in corpus contains DLMO figure but not full methods/results.,OpenAlex work abstract (api.openalex.org/works/W3132047372; accessed 2026-02-14) + Supplemental PDF (current pdf_path) shows DLMO figure (no full paper text).,1c43e085c8ea5730
